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Background: Moderate and chronic consumption of red wine protects against 
cardiovascular disease. Wine is a complex matrix containing multiple molecules whose 
concentrations can vary from one bottle to another. Therefore, the delineation of the putative 
cardioprotective components in wine such as alcohol, resveratrol and melatonin is very 
challenging when using commercially available red wine. 
Aim: We aimed to use synthetic wine, whose composition is well characterized, to explore 
whether the presence of alcohol, resveratrol and melatonin (as found in commercial wines) 
contributes to the cardioprotective effect of chronic and moderate consumption of red wine 
(equivalent to 2 glasses of wine/day) in an animal model. Additionally, we hypothesized that 
synthetic wine enriched with resveratrol and melatonin confers cardioprotection via 
improvement of overall antioxidant profile. 
Methods: The drinking water of male Long Evans rats was supplemented with synthetic 
wine (12% alcohol v/v) with/without resveratrol (100µg/L) and/or melatonin (0.075μg/L) to a 
final concentration corresponding to the concentration found in 2 glasses of wine per day. 
After 14 days of treatment, hearts were perfused on the Langendorff system and subjected 
to 30 minutes global ischemia followed by 60 minutes of reperfusion. Functional parameters 
were recorded throughout the experiments and infarct size was measured at the end of the 
protocol. Functional recovery (heart rate x left ventricular developed pressure), measured at 
60 minutes of reperfusion, was expressed as a percentage of baseline value. Blood plasma 
was collected when harvesting the heart to measure total antioxidant capacity, lipid 
peroxidation (thiobarbituric acid reactive substances (TBARS) assay), superoxide dismutase 
(SOD) and catalase activity. 
Results: Control hearts subjected to ischemia/reperfusion presented a functional recovery of 
11±2%. Pre-treatment with synthetic wine with/without melatonin or resveratrol did not 
improve functional recovery (15±6%,12±1%, 19±4% respectively, n.s. vs control). However, 
addition of both melatonin and resveratrol in synthetic wine improved functional recovery to 
32±5% (p<0.01 vs control). No significant changes were identified amongst the treatments 
when quantifying antioxidant enzyme activity in the form of SOD or catalase. However, 
synthetic wine enriched with both melatonin and resveratrol significantly increase lipid 
peroxidation (TBARS: 16.3±0.9 µmol/mL vs. 8.5±0.4 µmol/mL for control; p<0.01).  
Conclusion: In conclusion, our data strongly suggest that the presence of melatonin and 
resveratrol in wine is required for cardioprotection with chronic moderate consumption of 
wine. Our data do not provide a role for the antioxidant activities of the wine as a possible 
mechanism for cardioprotection. Our findings support that the combination of melatonin with 













1.1 Prevalence of cardiovascular disease  
Non-communicable diseases (NCDs) can be defined as all the diseases, which are non-
infectious and non-transferable among people. NCDs include heart disease, most cancers, 
diabetes, chronic kidney disease and Alzheimer’s disease amongst others. The World 
Health Organisation (WHO) reports that NCDs are the leading cause of death in the world, 
representing over 60% of all deaths (WHO, 2011). Of the 57 million global deaths in 2008, 
36 million were due to NCDs. NCDs have surpassed communicable diseases as the world’s 
major disease burden, with cardiovascular disease (CVD) remaining the principal global 
















CVD is expected to grow to more than 23.6 million by 2030 if no adequate 
prevention/therapies are put in place (Mendis, Puska et al. 2012). CVD associated morbidity 
Figure 1: Distribution of global non-communicable disease by cause of death in both sexes 
From WHO/WHF/WSO: Global Atlas on Cardiovascular Disease Prevention and   Control. 





predominantly affects both men and women in low-and middle income countries (LMIC) 
(Figure.2)  where 80% of these deaths occur predominantly at younger ages compared with 
higher income countries (Abegunde, Mathers et al. 2007). CVDs have reached epidemic 
proportions in Sub-Saharan Africa (SSA) (Alberts, Urdal et al. 2005, Gersh, Sliwa et al. 
2010, Ikem, Sumpio 2011). Previously, conditions such as ischemic heart disease (IHD) and 
angina were considered a rarity in SSA (Walker, Sareli 1997, Seedat, Mayet et al. 1992). 
However, there has been a recent increase in both prevalence and incidence in the number 
of patients presenting with IHD (Mensah 2008), in part as a result of decreased access to 
effective and equitable healthcare services in those countries (Abegunde, Mathers et al. 
2007, Smith, Collins et al. 2012). Other key factors underlying the increasing prevalence of 
CVD in developing countries such as South Africa include: the ongoing change in nutrition 
patterns, the increase in weight and obesity, the decrease in physical activity and high levels 
of stress as well as the increase of urbanization (Alberts, Urdal et al. 2005). These lifestyle 
factors, associated with obesity and poor nutrition, lead to the emergence of well determined 






















In South Africa, although the continued epidemic of human immunodeficiency virus/acquired 
immunodeficiency syndrome (HIV/AIDS) is responsible for 29%and 36% of deaths in men 
and women, respectively (Shisana, Rehle et al.2013), CVD represents a major burden. IHD, 
hypertension and stroke account for more than a third of deaths in the population older than 
65 years (Gaziano, Thomas A 2010). The burden of CVD is predicted to increase 
Figure 2: Proportion of deaths due to CVD by country income level 





substantially in South Africa over the next decade if measures are not taken to slow down 
this burden (Mayosi, Flisher et al. 2009).   
 
 
1.2 Ischemia/ reperfusion 
1.2.1 Definition  
 
IHD is a condition that affects the supply of blood to the myocardium. Myocardial ischemia 
occurs when blood flow to the myocardium is decreased by a partial blockage of the 
coronary arteries and thus, reduces the myocardium oxygen supply. Complete blockage of 
the coronary arteries results in deficient oxygenation and nutrient supply to the 
cardiomyocytes, leading to damage and necrosis of the tissue, which is known as a 

















In a large majority of cases, myocardial ischemia is confined to specific regions of the 
myocardium and is termed regional ischemia. However, there are some conditions which 
can lead to the entire myocardium becoming ischemic (global ischemia), such as open-heart 
surgery in patients undergoing coronary artery bypass grafting, valve replacement therapy or 
heart transplant. While restoring blood flow to the ischemic area is essential to save 
threatened cardiomyocytes either by the use of pharmacological therapy with thrombolytics 
or through physical means with angioplasty, reperfusion is paradoxically associated with a 





cascade of deleterious effects in cardiomyocytes leading to ischemia/reperfusion (IR) injury 
(Yellon, Hausenloy 2007). 
 
1.2.2 Pathophysiology  
Ischemic injury  
The absence of oxygen halts cellular oxidative phosphorylation, leading to mitochondrial 
membrane depolarization, adenosine triphosphate (ATP) depletion, and inhibition of 
mitochondrial contractile function (Lesnefsky, Tandler et al. 1997, Reimer, Hill et al. 1981). 
This process is aggravated by the breakdown of available ATP as a result of ATP hydrolysis 
and increase in mitochondrial inorganic phosphate (Halestrap, Clarke et al. 2004). In the 
absence of oxygen, cardiomyocyte metabolism changes to anaerobic glycolysis, resulting in 
accumulation of lactate which reduces intracellular pH (Avkiran, Marber 2002, Kloner, Bolli et 
al. 1998). These changes lead to modifications in cardiomyocyte physiology and structure, 
including mitochondrial and sarcolemmal injury and alterations in intracellular calcium 
handling (Meissner, Morgan 1995). If the ischemic insult is limited in time, the damage is 
reversible, and restoration of blood flow during this period will lead to recovery of normal 
function. However, if ischemia persists for an extended period of time, this damage becomes 
irreversible and cell death occurs. Therefore, early restoration of oxygenated blood to the 
ischemic myocardium is required to limit infarct size (Simoons, Brand et al. 1985). Ironically, 
the return of blood can cause further cardiac damage and is referred to as reperfusion injury.  
Reperfusion injury  
The reintroduction of oxygen and energy into an ischemic cellular environment triggers 
additional events that produce further cardiomyocyte damage collectively called reperfusion 
injury. Several factors contribute to reperfusion injury. They include aggregation of 
inflammatory mediators (Frangogiannis, Smith et al. 2002), calcium overload (Zimmerman, 
Hülsmann 1966, Garcia-Dorado, Ruiz-Meana et al. 2012) and oxidative stress (Garlick, 
Davies et al. 1987, Zweier, Flaherty et al. 1987) (Figure. 4). Oxidative stress is a disturbance 
in the balance between the production of free radicals and antioxidant defences (Sies 2000). 
Reperfusion of ischemic cells results in the formation of potentially toxic free radicals, 
including hydroxyl radicals and superoxide anions. Free radicals harm cardiomyocytes 
directly by altering membrane proteins and phospholipids leading to metabolic and structural 
changes (Tsai, Sun et al. 2008, Kaplan, Babusikova et al. 2003). For instance, oxygen 




(Verma, Fedak et al. 2002).The role of free radicals as a source of significant myocardial 
damage is further illustrated by studies demonstrating that free radical scavengers, such as 
superoxide dismutase, administered during reperfusion help preserve myocardial function 






Furthermore, during an ischemic period, intracellular calcium increases due to impaired 
calcium handling and sarcolemmal damage (Meissner, Morgan 1995). This process can be 
worsened with reperfusion. The restoration of a normal extracellular pH after reperfusion 
produces a hydrogen gradient across the cell membrane. The sodium/hydrogen exchanger 
is activated and causes an influx of sodium into the cytosol. Under physiological conditions, 
the resulting increase in intracellular sodium would be corrected by the sodium/potassium 
ATPase. However, this channel may not function normally after a period of ischemia due to a 
lack of energy and structural damage. In this setting, the sodium excess causes the 
sodium/calcium channel to run in reverse, producing an influx of calcium into the calcium-
overloaded cell. Although the pathophysiology of reperfusion injury offers itself to potential 
therapeutic strategies, few therapies have made their way into clinical practice. A possible 
Figure 4: Graphical representation of the pathogenesis of reperfusion injury 







reason for this effect is that various mechanisms contribute to the consequences of IR injury. 
Thus, the impact of a therapy targeted to a single component of the pathophysiology may be 
weakened in clinical practice. 
Oxidative stress 
Oxidative stress is essentially an imbalance between the production of free radicals and the 
ability of the body to counteract or detoxify their harmful effects through neutralization by 
antioxidants (Sies 2000). Free radicals are oxygen containing molecules that have one or 
more unpaired electrons, making them highly reactive with other molecules. Free radicals 
can chemically interact with cellular components such as DNA, proteins or lipids and steal 
their electrons in order to become stabilized. This, consequently, destabilizes the cellular 
components or molecules which then seek an electron from another molecule, triggering a 
large chain of free radical reactions. Oxygen by-products are relatively unreactive but some 
of these can undergo metabolism within the biological system to give rise to highly reactive 
oxidants. For instance, the diatomic oxygen molecule has two unpaired electrons, if this 
molecule accepts an electron the product is a superoxide radical. Many free radicals have 
important intermediates such as hydrogen peroxide and peroxynitrite which are not free 
radicals but which are highly reactive and may be responsible for some of the biological 
effects attributed to free radicals.  
Free radicals and their non-radical reactants are recognized as critical mediators of cardiac 
injury during ischemia and reperfusion. They have been implicated in cardiac cell death, post 
ischemic contractile dysfunction and in chronic cardiovascular diseases. The main source of 
free radicals in IR injury is the mitochondrial electron transport chain. During the reduction of 
molecular oxygen into biological energy through the four mitochondrial complexes the 
reduction process is not completely efficient and 1%-4% of available oxygen is normally 
incompletely reduced and leaks from the electron transport chains in the form of a 
superoxide radical. This process however becomes significantly accelerated at suboptimal 
oxygen tensions or after mitochondrial injury and is believed to be the primary source of 
ROS during IR injury. Cellular hypoxia decreases the activity of cytochrome oxidase. When 
oxygen is reintroduced, leakage of free radicals from proximal complexes is greatly 
accelerated. Although it was previously believed that ROS formation occurred primarily or 
solely at reoxygenation after ischemia, it is now known that significant formation of ROS 
occurs during ischemia from residual superoxide. This has been demonstrated in 
cardiomyocytes (Vanden Hoek,Li et al.1997) and in the whole heart (Kevin, Camara et 
al.2002,Kevin, Novalija et al.2003). Most peroxide is dismutated by manganese superoxide 




mitochondrial membranes. The remainder exits the mitochondria through anion channels in 
the mitochondrial membrane and is then rapidly converted to hydrogen peroxide in the 
cytoplasm, either spontaneously, or when catalyzed by copper superoxide dismutase. 
Hydrogen peroxide is reduced to water and oxygen by catalase and glutathione peroxidase. 
Alternatively, hydrogen peroxide reacts with transition metals, to generate hydroxyl radical.  
Possible future cardioprotective therapies  
Currently, there are few promising therapies that can effectively protect the heart against IR 
injury. Novel approaches as potential adjunctive therapies to current reperfusion strategies 
such as coronary angioplasty and thrombolytics are required to provide further 
cardioprotection in the setting of MI to reduce morbidity and mortality. The discovery of 
ischemic pre-conditioning and post-conditioning have emerged as promising experimental 
therapies against IR injury. In each case, protection is conferred by repeated short bouts of 
ischemia interspersed with bouts of reperfusion either before or after a potential lethal 
ischemia (Murry, Jennings et al. 1986, Zhao, Corvera et al. 2003). Experimental and clinical 
evidence suggests that both of these strategies are promising therapies to protect the heart 
against IR injury (Murry, Jennings et al. 1986, Zhao, Corvera et al. 2003, Staat, Rioufol et al. 
2005, Thibault, Piot et al. 2008). The signalling pathways that mediate ischemic pre- and 
post-conditioning can be initiated by a large variety of agents including adenosine (Liu, 
Thornton et al. 1991), bradykinin (Goto, Liu et al. 1995), sphingolipids (Lecour, Smith et al. 
2002) and insulin (Jonassen, Sack et al. 2001). These protective effects are mostly mediated 
via the activation of Reperfusion Injury Salvage Kinase (RISK) (Yellon, Hausenloy 2007, 
Yellon, Baxter 1999) and Survivor Activating Factor Enhancement (SAFE) (Lecour 2009) 
pathways (Figure.5). The RISK pathway includes activation of the prosurvival kinases Akt 
and extracellular regulated kinase 1/2 (Erk1/2) at the time of reperfusion while the SAFE 
pathway includes the activation of the cytokine tumour necrosis factor alpha (TNFα) and the 
transcription factor signal transducer and activator of transcription-3 (STAT-3) (Hausenloy, 


























Additionally, ischemic conditioning can also be applied remotely when it is performed by 
small episodes of ischemia-reperfusion in an organ separate to the heart (Przyklenk, Bauer 
et al. 1993). However, despite an improved understanding of the pathophysiology of IR injury 
and encouraging preclinical trials of multiple agents, most of the clinical trials to prevent 
reperfusion injury have been disappointing. This could be attributed to several reasons; one 
being that the presence of comorbidities may impact the efficacy of the treatment see review 
(Heusch 2013). For instance, a study by Engbersen and colleagues demonstrated that 
although type 1 diabetes patients were more tolerant to forearm IR injury compared to 
healthy controls, the efficacy of ischemic preconditioning was reduced in patients with type 1 
diabetes mellitus (Engbersen, Riksen et al. 2012). Despite these problems, adjunctive 
therapies to limit IR injury remain an active area of investigation as there is a need for 
alternative therapies which could limit the damage of IR injury. Thus, targeting lifestyles 
would present a major benefit as it is inexpensive relative to medication and therefore would 
be a better approach for low and middle income countries (LMIC). 
 
1.3 Lifestyle factors for cardiovascular disease 
The majority of CVD is caused by risk factors that can be controlled, treated or modified 
such as high blood pressure, cholesterol, overweight/obesity, tobacco use, lack of physical 
activity and diabetes (Yusuf, Hawken et al. 2004, Steyn, Sliwa et al. 2005). However, there 
are also some major CVD risk factors that cannot be controlled which include age, gender 
and family history (Jousilahti, Vartiainen et al. 1999). 
Figure 5:  Schematic diagram showing the RISK and SAFE pathway. Both 
pathways may confer cardioprotection 





With all the factors considered, an unhealthy lifestyle can contribute up to 80% of 
cardiovascular deaths, whilst modest reductions in risk-associated behaviours can have 
exponential benefits (Cheng, Zhao et al. 2009). For example, a 0.5% reduction in risk factors 
can result in as much as a 23% decrease in mortality.  
The role of diet is crucial in the development and prevention of CVD. Diet is one of the major 
factors that can change an individual’s risk of acquiring CVD. IHD has a low incidence in 
some developed countries such as Italy and France, leading to a higher life expectancy in 
Mediterranean areas compared to Northern European countries and the United States of 
America (USA) (Martínez-González, García-López et al. 2011, Pierucci, Misciagna et al. 
2012). Diet and lifestyle related factors are suggested to be responsible for this advantage 
(Estruch, Ros et al. 2013). The role of diet in IHD has been well documented for the past 
century and substantial evidence about the protection by some food items and nutrients is 
currently available (Valls-Pedret, Lamuela-Raventós et al. 2012, Urpi-Sarda, Casas et al. 
2012). The Mediterranean diet, first studied by Keys and Grande in 1959 as the traditional 
dietary pattern found in areas of Southern Italy and Crete, has attracted significant interest 
(Keys, Anderson et al. 1965). The traditional Mediterranean diet is characterized by high 
intake of olive oil, nuts, vegetables, and cereals, a moderate intake of fish and poultry, a low 
intake of dairy products and wine in moderation (Huxley, Clifton 2013, Willett, Sacks et al. 
1995). Several observational studies and secondary prevention trials such as the Lyon diet 
heart study have consistently shown that adherence to the Mediterranean diet has 
considerable benefit with respect to cardiovascular risk (Sofi, Abbate et al. 2010, Michel de 
Lorgeril, Salen et al. 1999).  Likewise, the INTERHEART study found five protective factors  
which may guard against CVD and include: maintaining an ideal weight, regular exercise, 
not smoking, eating a diet rich in fruit and vegetables as well as a moderate intake of alcohol 
(2-3 glasses/day) (Yusuf, Hawken et al. 2004) (Figure.6). Until recently, alcohol consumption 
was frequently overlooked as an important part of the diet. Alcohol, more specifically wine, is 
































1.4 Red wine as a cardioprotective agent  
1.4.1 Definition of red wine 
Wine is an alcoholic beverage made from fermented grapes. Although the primary 
ingredients of wine include grape berry components including water, the end product yields a 
complex composition of compounds mostly as a result of the fermentation process. The final 
product can contain multiple chemical compounds varying in amounts from one part per 
hundred to parts per billion. To date, more than 1000 compounds have been identified in 
wine (Soleas, Diamandis et al. 1997). The water content represents from 80 to 85% of the 
wine total mass and is principally derived from grape berries. The alcohol content differs 
amongst wines from 9% to 16% and is achieved with fermentation by yeast which converts 
sugars into alcohol and carbon dioxide. The most abundant alcohol in wine is ethanol. Under 
standard fermentation conditions, it can sometimes accumulate to nearly 16%, but generally, 
ethanol concentration ranges between 10 and 13%, depending mainly on the sugar content 
of the grape, the temperature and the yeast strain. Phenols are derived from the seeds, skin 
and vine stems and can be produced by yeast metabolism. Phenols affect the taste, 
appearance, fragrance and antimicrobial properties of the wine. Other compounds found in 
wine include: organic acids, glycerol, biogenic amines minerals and amino acids, most of 
these compounds are found in low concentrations of not more than 100mg/L (Waterhouse, 
2002) (Figure.7).  
 
Figure 6: Five lifestyle changes that can protect against cardiovascular death 
From  Opie.L ,2011 , Living longer, living better: exploring the heart-mind connection , Oxford 
















1.4.2 Cardiovascular benefit of red wine 
In recent years, the benefits of daily moderate consumption of alcoholic beverages, 
particularly of red wine, in the prevention of heart disease has received increasing attention 
and debate (Klatsky, Armstrong et al. 1990). Alcohol intake from any type of alcoholic 
beverage appears to be beneficial, but some studies suggest that red wine confers 
additional health benefits (Thornton, Symes et al. 1983). The cardioprotective effects of red 
wine have been accredited mostly to several polyphenolic antioxidants. The proposed 
mechanisms for the observed cardioprotective effects have included, amongst others, 
inhibition of low density lipoprotein (LDL) cholesterol (Frankel, German et al. 1993), 
increased high density lipoprotein (HDL) cholesterol (Gaziano, Buring et al. 1993), reduction 
or inhibition of platelet aggregation (Renaud, Beswick et al. 1992), increased free radical 
scavengers (Sánchez‐Moreno, Larrauri et al. 1999, Saint-Cricq de Gaulejac, Glories et al. 
1999) and the increased activation in expression of several cardioprotective oxidative stress 
inducible proteins including heat shock proteins (HSPs) (Sato, Maulik et al. 2002). 
 
1.4.3 Epidemiological evidence of red wine-induced 
cardioprotection 
1.4.3.1 The French paradox 
In 1819, cardiologist Dr Samuel Black noticed a high incidence of coronary obstructions at 
autopsies in Ireland, however, there was an unexplainable rarity of reports of such 
obstructions coming from France. He attributed this difference to ‘the French’ habits and 
Figure 7: Pie chart showing red wine component composition 




modes of living’ see review (Evans 1995). In 1979, St Leger and colleagues drew attention 
to the cardioprotective properties of wine when they described an inverse relationship 
between wine consumption and the risk of mortality from CVD in several countries from 
North America and Europe (St Leger, Cochrane et al. 1979). Almost two decades later in 
1991, a popular investigative documentary television program in the United States, called 60 
minutes, introduced to the public that chronic moderate consumption of red wine in France 
could be responsible for the low incidence of coronary heart disease in this country, despite 
an increased intake of saturated fat comparable to other developed countries (Renaud, de 
Lorgeril 1992) (Figure.8). This observation became known as the “French paradox” and was 






It is possible that the supposed protection conferred by red wine may result from a complex 
and partially understood association of wine intake with medical, psychosocial, religious 
and/or demographic confounding factors. Since the possibility of a randomized controlled 
study is low, the relationship between wine intake and the supposed lower risk of CVD 
requires careful analysis. Growing evidence supports that red wine might afford a degree of 
Figure 8: Graph showing the low mortality rate of CHD in France in comparison to other 
European countries despite similar intake of high saturated fats 




coronary protection in part due to multiple confounding factors. For example, moderate wine 
drinkers may represent as a proxy of higher socioeconomic status, superior heath status and 
lower CV risk (Hansel, Thomas et al. 2010). In addition, it has been demonstrated that 
moderate wine drinkers consume a healthier diet when compared with heavy drinkers or 
abstainers (Ruidavets, Bataille et al. 2004, Johansen, Friis et al. 2006).  
 
1.4.4 Experimental evidence of red wine induced 
cardioprotection 
 
A few studies have demonstrated the cardioprotective effect of red wine against IR in an 
isolated rat heart model. An acute treatment of red wine extract (1µg/ml) protects rat hearts 
against IR injury by reducing infarct size as well as an improving developed pressure 
compared to the control rats (Sato, Ray et al. 2000). The cardioprotective effect of red wine 
was further illustrated in a study which examines whether the flesh and seeds of red grapes 
possess any cardioprotective abilities. Hence, rats chronically fed with flesh of grapes 
(2.5mg/kg) or seeds of grapes (2.5mg/kg) for 30 days are protected against IR injury, as 
demonstrated by improved post-ischemic ventricular recovery and reduced myocardial 
infarct size compared to the control groups treated with water only (Falchi, Bertelli et al. 
2006). These studies demonstrate that red grapes contain components that are 
cardioprotective independent of fermentation derived molecules which could be responsible 
for this protective effect. 
Unfortunately, most of these studies have investigated the cardioprotective effect of red wine 
with particular interest in specific components of red wine and not the wine in its entirety. 
One of the few studies that investigated the cardioprotective effect of whole red wine was 
conducted by  Lamont and colleagues who demonstrated that chronic pre-treatment with red 
wine (for 10 days) at a concentration equivalent to 2-3 glasses/day was beneficial in male 




1.5 Possible cardioprotective components in red wine  
Red wine contains a complex mixture of bioactive compounds, including flavonols, 
monomeric and polymeric flavanoids, highly coloured anthocyanins, biogenic amines and 
phenolic acids. Studies have shown that some of these compounds have health advantages 




components in red wine that have been suggested to elicit cardioprotection: alcohol, 
resveratrol and melatonin. Each will be reviewed in detail, specifically with regards to 
biological mechanisms supporting the cardiovascular benefits of these components in 
moderate consumption of wine. 
 
1.5.1 Alcohol  
1.5.1.1 Epidemiological evidence  
Substantial evidence suggests the consistent negative correlation between alcohol 
consumption and the incidence of CVD. Numerous studies from the late 1970s onwards 
have reached a consensus that people who consume one to two drinks per day have a lower 
CVD risk compared with abstainers and binge drinkers (Figure.9), a relationship described 
as a J-shaped or U-shaped curve (St Leger, Cochrane et al. 1979, Connor 2006). Moderate 
alcohol consumption mostly equivalent to 1 drink per day for women and 2 drinks per day for 
men has been found to decrease the incidence and adverse consequences of heart disease 
in several epidemiological studies (Mukamal, Chung et al. 2006). The definition of one 
alcohol drink varies by country and publication. Terms such as light, moderate and heavy 
drinking are unclear. For instance, one drink is 8 g of ethanol in England, 12 g in USA, and 
20-24g in Japan. According to Dietary Guidelines for Americans, moderate drinking is no 
more than 1 drink (12 g of ethanol) per day for women and no more than 2 drinks (24 g of 
















Figure 9: A graphical representation of J-shaped mortality curve for 
alcohol consumption. 
























This phenomenon has been further illustrated by a study from Gronbaek et al, who 
investigated the relationship between various types of alcoholic beverages and mortality in a 
population comprised of men and women between ages 30 to 79 (Gronbaek, Deis et al. 
1995). The findings included the reduction of the relative risk of death from 1.00 in 
abstainers to 0.4 for those who drank 3 to 5 glasses of wine per day. With regards to the 
intake of beer, 3 to 5 bottles per day conferred a reduction in risk of 0.72 compared to 
abstainers. In contrast, consumption of 3-5 drinks of spirits per day was linked with 
increased mortality. Furthermore, the study concluded that light and moderate wine drinking 
is associated with dose-dependent decrease in all-cause mortality that is attributed to a 
decrease in cardiovascular-related disease. The health benefits and mechanisms observed 
might be heavily influenced by social, genetic and environmental factors. Hence, a recent 
study by Leong et al demonstrated that alcohol consumers living in South Asia and the 
Middle East, in contrast to the rest of the world, did not display protection against MI (Leong, 
Smyth et al. 2014). In some instances, populations from particular South Asian countries 
showed significantly elevated risk after adjusting for quality of diet, body composition and 
classic vascular risk factors. This study suggests that the negative effects of alcohol are not 
exclusive to frequent binge drinkers but, in addition, can extend to light-to-moderate drinkers. 
Thus, the beneficial effects of alcohol intake in human health should be better defined, and 
additional research is required before any suggestions can be made to initiate light-to-
moderate consumption of alcohol. 
 
1.5.1.2 Experimental evidence of alcohol induced cardioprotection 
Animal experiments have been performed to mimic human drinking patterns in order to 
investigate whether moderate alcohol consumption could protect the heart against IR injury. 
There is evidence that long-term alcohol consumption may improve survival after myocardial 
infarction. Miyamae et al, found that prolonged consumption of 10% ethanol protects against 
IR injury in guinea pig hearts (Miyamae, Diamond et al. 1997). Particularly, hearts isolated 
from animals fed with ethanol for 3-12 weeks demonstrated better recovery and less 
myocyte damage after IR injury compared to controls receiving water only. The authors 
attributed the cardioprotective effect to an ethanol-induced adenosine receptor activation, an 
important mediator of ischemic pre-conditioning. Furthermore, Kobuyashi et al, 
demonstrated that ethanol added to the buffer of perfused rat hearts prior to anoxia, followed 
by reoxygenation decreased myocardial injury (Kobayashi, Ashraf et al. 1987). However, this 
study did not determine whether chronic ethanol consumption produced protection against 
reperfusion injury in the absence of ethanol. Upon review of varied literature, the trend 




response is inversely correlated to the duration of exposure (Diamond, Gordon 1994). 
Studies by Miyamae et al have shown that doses as low as 2.5% and 5% ethanol produced 
partial cardioprotection after 3 weeks of exposure, however full protection is maximal after 6 
weeks of treatment independent of the dose of alcohol given (Miyamae, Diamond et al. 
1997). Logically, higher concentrations of ethanol produced maximum protection at 3 weeks 





1.5.1.3 Does alcohol contribute to red wine-induced 
cardioprotection? 
Although multiple experimental and clinical studies support a cardiovascular benefit of 
chronic consumption of alcohol, other studies strongly suggest that the cardioprotective 
effect of red wine goes beyond alcohol content. A study conducted by Keevil et al, showed 
substantial inhibition of platelet activity in healthy humans after drinking two cups of purple 
grape juice for one week (Keevil, Osman et al. 2000). A study on coronary heart disease 
patients showed that 250mL of de-alcoholized Greek red wine was able to decrease arterial 
stiffness (Zilkens, Burke et al. 2005). Interestingly, red grape juice had similar 
cardioprotective properties to that of red wine. Patients undergoing hemodialysis and who 
consumed red grape juice for 14 days, had a significant reduction in plasma monocyte 
chemoattractant protein 1 concentration and LDL concentration (Castilla, Echarri et al. 
2006). In addition, patients displayed higher levels of HDL compared to patients not 
consuming red grape juice. Experiments conducted at the Hatter Institute did not 
demonstrate any cardioprotective effect of alcohol in isolated hearts subjected to IR injury 
after 2 weeks of feeding with alcohol equivalent to 2-3 glasses of wine/day (Lamont, 
Blackhurst et al. 2012).  Rats pre-treated with alcohol only (6% and 12%) extracted from red 
wine did not attain protection against IR injury compared to the untreated controls. However, 
rats pre-treated with red wine containing either 6% or 12% alcohol demonstrated similar 
cardioprotection against IR injury. Therefore suggesting that alcohol is not the sole 









1.5.2 Resveratrol  
1.5.2.1 Definition and structure  
Resveratrol (3,5,4’-trihydroxystilbene) was first isolated from the roots of white hellebore in 
1940, and later, in 1963, from the roots of Polygonum Cuspidatum, a plant used in traditional 
Chinese and Japanese medicine (Nonomura, Kagawnaa et al.1963). Resveratrol is a 
stilbenoid, a type of natural phenol and a naturally occurring phytoalexin produced by a wide 
variety of plants in response to stress, injury, ultraviolet (UV) irradiation and fungal infection 
as part of their defence mechanism (Langcake, Pryce 1976). Resveratrol can be obtained 
exogenously from various dietary sources which include red grapes, peanut butter, dark 
chocolate and legumes (Cassidy, Hanley et al. 2000). 
 Resveratrol initially generated modest interest until 1992, when it was suggested to explain 
the cardioprotective effects of red wine (Siemann, Creasy 1992). Subsequently, multiple 
studies have shown that resveratrol can prevent or slow down the progression of a wide 
variety of diseases including cancer (Jang, Cai et al. 1997), atherosclerosis (Wang, Zou et 
al. 2005), heart failure (Rimbaud, Ruiz et al. 2011) and IHD (Ray, Maulik et al. 1999). 
Resveratrol exists as two geometric isomers, a cis and a trans form (Figure.10). Trans-
resveratrol is suggested to be the isomer that contributes to the cardioprotective properties 
of red wine (Orallo, Alvarez et al. 2002) through endothelium-dependent vasorelaxant 
activity, possibly mediated by nitric oxide (NO) release from endothelial cells (Fitzpatrick, 













Figure 10: A graphical representation of the bioactive conformations of 
resveratrol. 








Cis-resveratrol is not a natural constituent of grape berries. However, cis-resveratrol has 
been detected in all wine analyses (Siemann, Creasy 1992). It is likely that cis-resveratrol 
derives from its trans isomer during vinification. Fresh grape skins contain 50 to 100 mg 
resveratrol per gram (Jeandet, Sbaghi et al. 1995), however, resveratrol concentrations 
show large variation in numerous types of wine (Figure.11). Concentrations of resveratrol in 
wine depend on multiple factors which include geographical origin (Goldberg, Ng et al. 
1996), wine type (Threlfall, Morris et al. 1999) and oenological practices (Jeandet, Bessis et 
al. 1995, Soleas, Goldberg et al. 1995). Another major factor is the fermentation process, 
contact with grape skins is important because resveratrol is largely produced by the skin and 
not the pulp of grapes which would explain its negligible concentration in white wine 














1.5.2.2  Cardiovascular benefit of resveratrol  
 
Many studies have demonstrated that resveratrol has a wide range of pharmacological 
properties. In the cardiovascular system, resveratrol is suggested to mediate its 
cardioprotective effects through several mechanisms such as its antioxidant activity, 






Figure 11: Different types of red wine and their resveratrol concentrations 



















Resveratrol has been shown to be effective in protecting against IR injury. In a study 
conducted by Mokni and colleagues, rats which were pre-treated with resveratrol 
(25mg/kg/day) for seven days and subjected to IR injury demonstrated cardioprotection as 
shown by improved post-ischemic ventricular recovery, improved antioxidant enzyme activity 
and reduced myocardial lipid peroxidation (Mokni, Hamlaoui et al. 2013).This effect was 
thought to be mediated by a reduction in reactive oxygen species (ROS) production. In 
another study, when resveratrol (100µmol/L) was administered prior to cardiomyocytes 
being subjected to two hours of simulated ischemia, there was increased cell viability by 
preventing apoptosis via increasing the expression of B-cell lymphoma 2, an anti-apoptotic 
factor (Shen, Wu et al. 2012). Additionally, there was a decrease in lactate dehydrogenase 
(LDH) release and increase in adenosine triphosphatase activity. These effects were 
mediated by activation of the cyclic guanosine monophosphate pathway and protein kinase c 
(PKC), a well-known mediator in ischemic preconditioning. 
In 2007, a study conducted by Penumathsa and colleagues highlighted the effect of 
resveratrol against IR injury. Male hypercholesterolemic Sprague-Dawley rats were fed a 2% 
cholesterol diet for 8 weeks, followed by a chronic treatment of resveratrol (20mg/kg/day) for 
2 weeks before being exposed to 30 minutes of global ischemia (Penumathsa, 
Thirunavukkarasu et al. 2007). Resveratrol-treated rat hearts displayed a significant 
reduction in infarct size, as well as improved functional recovery, compared to untreated 
hypercholesterolemic rat hearts after an IR insult. In vitro human cardiac specimens treated 
with resveratrol (10 μM) and placed in a microperfusion chamber, displayed a significant 






reduction in apoptosis, compared to control cardiac specimens (Usta, Mustafi et al. 2011). 
These findings suggest that resveratrol protects the heart against the detrimental effects of 
IR injury. Although many studies have confirmed the cardioprotective effects of resveratrol, 
most of them have used a concentration far larger than the resveratrol concentration found 
in red wine (0.5 to 13.5mg/L).  
 
1.5.2.3 Does resveratrol contribute to red wine 
cardioprotection? 
Lamont and colleagues observed that an acute treatment of resveratrol (2.3mg/L) 
corresponding to the concentration found in red wine significantly reduced infarct size in 
mouse hearts, but not in tumor necrosis factor (TNF) receptor 2 knockout or STAT3-deficient 
mice (Lamont, Somers et al. 2011). This data suggests that resveratrol protects via the 
SAFE prosurvival signalling pathway. In addition, when rats were pretreated with resveratrol 
(7mg/L) chronically for 10 days, resveratrol failed to improve post-ischemic functional 
recovery or reduce infarct size (Lamont 2009). Despite abundant experimental studies that 
have been carried out in animal models, investigations regarding the safety and beneficial 
effects of resveratrol in humans through randomized clinical trials are rare. Recently, a study 
conducted by Semba and colleagues involving 800 people from the Chianti region of Italy  
investigated whether dietary resveratrol had any links with cancer and CVD death rates 
(Semba, Ferrucci et al. 2014) . The study found that the risk of death during the nine-year 
follow-up period was no different for people with the highest levels of metabolites 
(breakdown products) of resveratrol in their urine, compared to people with the lowest levels. 
There were no differences in the risk of CVD. However, one of the limitations of the study 
was that resveratrol levels were measured using 24 hour urine samples that looked for 
breakdown products of resveratrol and this may not be representative of the participants’ 
usual pattern of consumption of red wine, berries and chocolate. Moreover, a recent study 
suggests that resveratrol could counteract the benefits of cardiovascular exercise in older 
men. The objective of the study was to investigate the effects of resveratrol supplements 
during high-intensity exercise. For the study, the men were required to increase their 
exercise levels and carry out high-intensity interval training three times a week for 4 weeks 
(Gliemann, Schmidt et al. 2013). In addition, the men were randomized to receive either a 
placebo or a 150-mg dose of resveratrol each day. The results showed that after 4 weeks, 
the physical fitness of the men who received resveratrol supplementation did not improve. 
However, those who received the placebo saw some benefits associated with physical 
activity, such as an increase in superoxide dismutase 2 (SOD2) gene expression associated 




sample size and did not control for confounding drug use. Furthermore, when resveratrol is 
given at a high dose it can become a pro-oxidant and could possibly cause damage in the 
heart. A study demonstrating this was conducted by Gurusamy and colleagues who found 
that resveratrol-induced autophagy occurred when resveratrol was given at higher doses 
(100mg/kg/day) (Gurusamy, Lekli et al. 2010).This effect was mediated by inhibiting the 
expression of rictor, a component that activates prosurvival kinase AKT. Of note, the field of 
resveratrol research has been tainted by scientific fraud by Dr Dipak Das who was charged 
with 145 cases of fabricated or false data (Naik 2011, Sen 2012). This has led to many of his 
scientific articles being retracted. 
 
1.5.3 Melatonin  
1.5.3.1 Definition and structure  
Melatonin (N-acetyl-5-methoxytryptamine) (Figure.13) was first isolated and identified in 
bovine pineal tissue in the late 1950’s by Lerner and colleagues (Lerner, Case et al. 1958). 
One of the earliest findings regarding the production of melatonin in the pineal gland was 
that it is primarily synthesized and secreted at night and that the circadian rhythm of 
melatonin is determined by the light-dark cycle (Reiter 1995). Apart from the pineal gland, 
multiple organs have the capability of producing melatonin including the gastrointestinal tract 
(Bubenik 2002) and the melanocytes in the skin (Slominski, Tobin et al. 2008). In more 
recent years, melatonin has demonstrated multiple functions, which include; strengthening 
the immune system (Maestroni 2001), slowing down cellular aging (Bonilla, Medina-
Leendertz et al. 2002) as well as regulating hormones involved in sexual maturation and 
reproduction in females (Cavallo, Ritschel 1996) and regulation of leptin in the 
gastrointestinal tract (Rasmussen, Boldt et al. 1999). Melatonin can be sourced exogenously 
from certain foods such as cherries (Burkhardt, Tan et al. 2001), rice (Hattori, Migitaka et al. 
1995) and meat (Tan, Zanghi et al. 2014). It can also be bought over-the-counter as a 
supplement to alleviate jet lag (Herxheimer, Petrie 2002) and most importantly can be 
sourced from red wine (Rodriguez-Naranjo, Gil-Izquierdo et al. 2011a). Melatonin is found in 
Vitis vinifera seeds during the onset of ripening of the grapeberries (Vitalini, Gardana et al. 
2011). Melatonin content in wine varies, depending on the grape type (Iriti, Rossoni et al. 
2006), its environment, genetics, harvesting process and storage (Lachman, Šulc et al. 
2009). Iriti and colleagues measured the melatonin content in eight different wines. The 
berry skin of the Nebbiolo contained the highest melatonin concentration (428.3±32.1pg/ml), 
whereas the Cabernet Franc contained the lowest concentration (2.4±0.6pg/ml) (Iriti, 




activator, results in an increase in the amount of melatonin in the skins of these grape 
berries. The presence of melatonin has been detected in both white and red South African 
wines, with large differences in quantites of melatonin from various wine estates (Albertyn 
2012). This finding could be due, in part, to the characteristics of each wine, which can be 
largely influenced by the agrometeorological conditions (i.e. influential factors in agricultural 
crop development are the weather, climate, horticulture, animal husbandary and forestry). 
There are several vineyards in the Western Cape region of South Africa. The location of 
these vineyards varies, geographically, from areas close to the coast (eg. Hermanus) to in 







Biosynthesis and physiological mechanism of action  
In the biosynthesis of melatonin, tryptophan is first converted by tryptophan hydroxylase to 
5-hydroxytryptophan, which is decarboxylated to serotonin.  The synthesis of melatonin from 
serotonin is catalyzed by two enzymes, arylalkylamine N-acetyltransferase which catalyzes 
the N-acetylation of serotonin to N-acetylserotonin. This enzyme controls the circadian 
rhythm of melatonin production by the pineal gland in all vertebrates. Its enzyme activity is 
highest at night time and its activity decreases upon exposure to light. Hydroxyindole-o-
methyltransferase is the last enzyme of the melatonin biosynthesis pathway which catalyzes 
the transfer of a methyl group from S-adenosyl-L-methionine onto N-acetyl-serotonin to 
produce melatonin (Figure.14) (Sugden 1989). 













Melatonin exerts its influence through membrane receptors. The three major membrane 
receptors with varying affinities for melatonin are currently identified as melatonin 1 (MT1) 
and melatonin 2 (MT2) (Morgan, Barrett et al. 1994), as well as relatively unknown melatonin 
3 (MT3), which shows homology to human quinine reductase 2, a detoxification enzyme 
(Mailliet, Ferry et al. 2004). Receptors MT1 and MT2 are members of the G protein coupled 
receptor (GPCR) family with seven transmembrane domains. Depending on the specific cell, 
melatonin activates a variety of different second messenger cascades after it binds to the 
membrane receptor. Melatonin receptors are present in various localizations of the 
cardiovascular system and both MT1 and MT2 have been found to be highly expressed in 
sections of isolated coronary arteries, aorta and left ventricular specimens from healthy 
hearts as well as patients with dilated and ischemic cardiomyopathy (Ekmekcioglu, 
Haslmayer et al. 2001). When melatonin binds onto MT1 receptors, it has a vasoconstrictive 
effect (Ting, Dunn et al. 1997) in contrast to MT2 receptors which has a vasodilatory effect. 
This demonstrates that melatonin has the potential to regulate blood pressure (Masana, 
Doolen et al. 2002). The activation of melatonin receptors results in a decrease in cyclic 
adenosine monophosphate (cAMP) and in phospatidylino-inositol-4,5-bisphosphate 
hydrolysis, which leads to vasoconstriction (Paulis, Simko 2007) .  
1.6.3.2 Cardiovascular benefit of melatonin  
In 1985, Muller and colleagues found that the likelihood for a MI to occur peaks between 9 
am and 11 am (Muller, Stone et al. 1985). During the rest of the day, MI occurs at a similar 
rate. This suggests that the occurrence of a MI is dependent on the circadian rhythm.  
The production of melatonin is influenced by the detection of light and dark by the retina of 
the eye. For instance, the production of melatonin is inhibited when the retina detects light 
Figure 14: The classic biosynthetic pathways of melatonin in vertebrates 





and is stimulated in the absence of light. Thus, melatonin production is lower during the 
daytime than at night-time see review (Reiter 1991).There is a correlation between MI 
incidence and presence of melatonin. A study by Dominguez-Rodriguez and collegues 
demonstrated that acute MI is associated with a nocturnal serum melatonin insufficiency as 
well as increased oxidative stress (Domínguez‐Rodríguez, Abreu‐González et al. 2002). 
Patients diagnosed with acute MI had lower glutathione peroxidise levels and did not show 
diurnal variation. In addition, lipid peroxidation levels in acute MI patients were increased 
and diurnal variation was also lost. 
Melatonin, given at varying concentrations (1, 10 and 50 μM) attenuated cardiac arrhythmias 
in an isolated male Sprague-Dawley rat heart model (Tan, Manchester et al. 1998). 
Furthermore, 10 μM of melatonin and 50 μM of melatonin reduced reperfusion ventricular 
induced fibrillation and arrhythmias in male Wistar rats subjected to IR injury (Szárszoi, 
Asemu et al. 2001, Dobsak, Siegelová et al. 2003). In an ex vivo setting, Lee and colleagues 
established the cardioprotective effect of melatonin against IR injury (Lee, Chen et al. 2002). 
Male Sprague Dawley rat hearts treated with melatonin (1.0 and 5.0 mg/kg) 10 min before 
occluding the left anterior descending artery and 45 min reperfusion, had a significant 
reduction in infarct size, reduced tachycardia and fibrillation, compared to the control group. 
Melatonin (10mg/kg) treatment of male Sprague Dawley rats for 4 weeks subjected to IR 
injury reduced the infarct size and LDH release, compared to vehicle treated hypoxic rats 
(Yeung, Hung et al. 2008). Male Wistar rats subjected to 30 min global ischemia and treated 
acutely with melatonin (50μM) had a significant reduction in infarct size with a reduction in 
LDH release, an indicator of necrosis, compared to untreated controls (Petrosillo, 
Colantuono et al. 2009). 
1.6.3.3 Does melatonin contribute to red wine-induced 
cardioprotection? 
Recent research conducted within the Hatter Institute for Cardiovascular Research in Africa 
has suggested the role of melatonin in red wine-induced cardioprotection. Chronic pre-
treatment with melatonin at the concentration found in red wine, protected the heart against 
IR injury (Lamont 2009). Likewise, isolated rat hearts treated acutely with melatonin at a 
concentration similar to that found in red wine (75 ng/L), demonstrated a significant reduction 
in infarct size in compared to untreated control hearts after an IR insult (Lamont, Somers et 
al. 2011). In STAT-3 knockout or TNF-α knock-out mice, pretreatment with melatonin 
(75ng/L) failed to reduce the infarct size after an IR insult. In addition, male Wistar rat hearts 
subjected to an acute administration of melatonin (75ng/L) had a significant expression of 
STAT-3 in the nucleus of cardiomyocytes. These data suggest that melatonin confers 




the Hatter Institute, the aim was to explore whether South African red and white wines confer 
a cardioprotective effect in relation to their melatonin content (Albertyn 2012). The results 
demonstrated that chronic moderate pre-treatment with both South African red and white 
wines improved the cardiac function of rats subjected to IR injury. However, after measuring 
the melatonin content in each South African wine, the data did not show a relationship 
between the melatonin content present in the wine and its’ cardioprotective effect. As wine 
may contain varying concentrations of melatonin and also other potential cardioprotective 
molecules from one bottle to another, it is difficult to establish if melatonin plays a vital role in 
red wine induced cardioprotection. Thus, in order to validate the role of melatonin in wine-
induced cardioprotection, we propose the use of a synthetic wine, whose composition is fully 


























































Aim and objectives 
A large number of epidemiological studies have demonstrated that chronic and moderate 
consumption of wine is associated with reduced cardiovascular disease. Elucidating the 
components found in wine which contribute to this cardioprotective effect may lead to the 
development of novel therapies against ischemic heart disease. Wine contains alcohol and 
natural antioxidant compounds, including resveratrol and melatonin, that have all been 
suggested to possess cardioprotective properties.   
Red wine is a highly complex matrix which contains over a thousand different molecules 
whose concentrations vary from one bottle of wine to another. Therefore, the delineation of 
the exact components in wine which confers cardioprotection is very challenging when using 
commercially available red wine. In the wine biotechnology field, the preparation of synthetic 
wine, with a chemical composition which is perfectly known and controlled, is often used to 
better understand the wine making process. This medium is designed to reflect the main 
nutrients used by yeast that are present in freshly prepared, highly clarified, grape juice. 
 
In the present study, we therefore hypothesised that synthetic wine, enriched with 
cardioprotective components such as resveratrol and/or melatonin, contributes to the 
cardioprotective effect of chronic and moderate consumption of wine. 
 
To explore this hypothesis, the following objectives will be pursued: 
1. In collaboration with the Wine Biotechnology Institute at the University of 
Stellenbosch, we will prepare a synthetic wine whose chemical and functional 
properties will be characterised. 
2. To investigate the effect of chronic and moderate consumption of synthetic wine 
enriched with melatonin and/or resveratrol in an ex vivo rat model of IR injury. Rats 
will be pretreated with water or synthetic wine containing or not melatonin and/or 
resveratrol. After 14 days of treatment, the hearts will be isolated and subjected to a 
global ischemia-reperfusion insult. Functional parameters and infarct size will be 
assessed as an endpoint 
3. To investigate the effect of a chronic treatment of synthetic wine with/without 
resveratrol and/or melatonin on antioxidant status in plasma of rats pretreated for 14 
days. Antioxidant capacity (ORAC, catalase and SOD assay) and markers of 
oxidative stress (TBARS assay) will be assessed in the plasma with the aim to 












Figure 15: A simplified diagram which illustrates a hypothetical setting whereby enriching 
synthetic wine with resveratrol and/or melatonin may contribute to the cardioprotective effect of 
chronic moderate consumption of wine 
ORAC- Oxygen radical absorbance capacity 































1 Production and validation of synthetic wine 
 
1.1 Production of synthetic wine 
Wine is an extremely complex matrix combining over a thousand different chemicals in it. In 
order to assess the effect of alcohol, resveratrol and/or melatonin in wine-induced 
cardioprotection, a simplified synthetic wine, whose composition is perfectly controlled was 
designed. Sugars (glucose and fructose) are used as the main energy source and organic 
acids as well as amino acids are used as nitrogen sources. 
The preparation of the synthetic wine is based on a method previously described by 
Henschke and colleagues (Henschke, Jiranek 1993). The composition of the synthetic wine 
is described in Appendix A. Briefly, sugars, organic acids, organic salts, amino acids, trace 
elements, vitamins and lipids were added into 600mL of deionised water. The pH of the 
medium was adjusted to 3.3 by adding potassium hydroxide and the volume was increased 
to 1L with deionised water before inoculation. 
Yeast strain and fermentation conditions 
The yeast strain used in this study was VIN13 (Anchor yeast, South Africa), a diploid 
saccharomyces cerevisiae strain used in industrial wine fermentations. Yeast cells were 
cultivated at 30°C in Yeast Peptone Dextrose (YPD) synthetic media 1% yeast extract 
(Biolab, Midrand, South Africa), 2% peptone, and 2% glucose (Sigma-Aldrich, Germany). 
Solid medium was supplemented with 2% agar (Biolab, South Africa). Fermentation bottles 
were inoculated with YPD cultures in the exponential growth phase to an  OD600 of 0.1. All 
fermentations were carried out under anaerobic conditions in 1L round-bottom flasks and 
sealed with rubber stoppers to provide better exclusion of oxygen with a carbon dioxide 
 outlet. The fermentation temperature was maintained at approximately 25°C, and no 
continuous stirring was performed during the course of the fermentation. The fermentations 
followed a time course of 23 days, and the bottles were weighed daily to assess the 
progress of fermentation. As the sugars were converted into alcohol and carbon dioxide by 
the yeast, the fermentation flask would weigh less on each day. The fermentation was 
considered complete when residual sugars in wine were lower than 2g/L and the 
fermentation flask weight stabilized. Alcohol content was measured and equalled to 12% 
(v/v). Once primary fermentation was completed there is a need for confirmation of the 
success of the fermentation process. The central Analytical Facility in the Wine 
biotechnology institute at the University of Stellenbosch completed these analyses including 
a test for residual sugars to confirm the dryness of wine and cessation of fermentation. The 




Produce grape juice 
medium 
Ferment grape juice 
medium for 23 days at 25°C 
Aliquot synthetic wine and 
store at 4°C 
analysis of the synthetic wine was complete, the wine was degassed with nitrogen before it 
was aliquoted into standard Bordeaux 750mL wine bottles and sealed with screw-top caps. 




Table 1: Post-fermentation analysis of the synthetic wine obtained from the Central 
Analytical Facility 
 
Acetic acid(g/L) D-Fructose(g/L) D-Glucose(g/L) Glycerol(g/L) 
0.8 0.0187 -0.0042 6.006 
 
 
 A wine is considered dry when residual sugars (D-fructose and D-glucose) are less than 
1g/L, in order to avoid re-fermentation of yeast. Analysis of volatile acids establishes a 
baseline that enables monitoring of potential spoilage problems throughout the storage life of 
a specific wine. At the post-fermentation stage, acetic acid, the main component of volatile 
acidity, may be formed by oxidation of ethanol in an aerobic environment. The acceptable 
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Figure 16: Simplified schematic diagram summarising the different steps in the 





Functional assays of synthetic wine 
A large number of epidemiological studies have demonstrated that moderate consumption of 
red wine is associated with reduced mortality and reduced IHD, an association popularized 
as the ‘French paradox”. Although red wines do not contain significant amounts of 
antioxidant vitamins such as vitamin C and E, their protective effects have been largely 
ascribed to phenolic components. It has been proposed that phenols act as antioxidants. 
Phenols have shown to be effective radical scavengers, with respect to lipid, protein and 
deoxyribonucleic acid (DNA) oxidation, which is determined mostly by their reactivity as 
hydrogen or electron donating agents. 
Red wine contains wood and yeast derived phenols, in addition to the large numbers of 
phenol compounds which originate from grapes, particularly the skins which are removed 
during the vinification of white wine. Thus, because of the different types of grapes used and 
the different production processes implemented, there are some fundamental differences in 
white and red wine composition in terms of the nature of polyphenols. 
In order to investigate the effect of synthetic wine-induced protection, it is essential to 
characterize the chemical and functional properties of the synthetic wine. 
1.2 Determination of concentration of total phenolic compounds in synthetic 
wine  
The Folin-Ciocalteu assay is the most commonly used procedure to determine the total 
phenolic content of food extracts. The concentration of synthetic wine phenolics was 
measured by using the Folin-Ciocalteu (F-C) method adapted from Waterhouse 
(Waterhouse 2002).The F-C assay is an in vitro colormetric assay based on the reduction of 
a phosphotungstate –phosphomolybdate complex by phenolic compounds. 
Wine samples (20µL) and gallic acid standards (20µL) were mixed with 1.58mL water in 5mL 
plastic tubes. Undiluted commercially available F-C reagent (100µL) was added to the tube 
and the mixture was vortexed and left at room temperature for 5 minutes. An aqueous 
sodium carbonate (20% m/v) solution (300µL) (refer to Appendix B) was added to the tube, 
vortexed and incubated at 40ºC for 30 minutes. The absorbance of the mixture was 
determined by spectrophotometry (Spectramax Plus 384, Molecular Devices, Labotec, South 
Africa) using Softmax Pro (Version 4.4) software at 765nm. A calibration curve was prepared 
using gallic acid ranging from 0 to 500 mg/L (Figure.17). The results were expressed in mg/L 








1.3 Measurement of total antioxidant capacity in the synthetic wine by the 
oxygen radical absorbance capacity (ORAC) assay 
Total antioxidant capacity was performed in synthetic wine using methods previously 
described by Cao and collegues (Cao, Alessio et al. 1993) using the oxygen radical 
absorbance capacity (ORAC) assay. This assay evaluates the intrinsic antioxidant protective 
effect of samples against oxidative degradation of a fluorescent molecule, fluorescein (3,6, 
dihydroxyspiro(isobenzofuran-1(3H), 9(9H)(xanthen)(disodium) (Sigma Aldrich, Germany), 
following mixing with AAPH (2,2′-azobis(2-amidinopropane)dihydrochloride), a peroxyl 
radical generator. The fluorescence intensity decreases as the oxidative damage of the free 
radicals released by AAPH progresses (Figure.18).  
 
 
y = 0.001x + 0.0735 
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Folin-Ciocalteau Gallic acid standard curve 


















































The protection against the free radicals by the synthetic wine is compared to known 
concentrations of the vitamin E water-soluble analogue Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylicacid (Sigma-Aldrich, Germany). The reactions were carried 
out in phosphate buffer (75mM, pH 7.4) and the final reaction volume was 300μL.  To each 
well of a 96-wellplate was added with diluted wine samples or trolox standards (50μL), 
phosphate buffer (50μL) and fluorescein (100µL) (refer to Appendix C). The mixture was pre-
incubated for 15 minutes at 37°C. AAPH solution (100μL; 32.1µM final concentration) was 
added rapidly using a multichannel pipette. The plate was automatically agitated prior to 
each reading. The plate was immediately placed in the Varian Cary eclipse fluorescence 
spectrophotometer reader (Set point tech., South Africa) and the fluorescence was recorded 
every 5 minutes for the first 30 minutes and every 15 minutes thereafter for the duration of 
the experiment. Fluorescence readings were carried out using excitation and emission filters 
at 485nm and 520nm, respectively. A blank using phosphate buffer in place of the wine 
sample, and eight calibration solutions using Trolox (between 1 and 8 nmol/mL final 
concentration) were analysed in the same run. AAPH and trolox solutions in phosphate 
buffer (75 mM,pH 7.4) were prepared daily and fluorescein was diluted from a stock solution 
(1.196mM) in the same phosphate buffer that was stored at 4°C. All sample reactions were 
measured in duplicate. 
A standard curve was generated using the known concentrations of trolox, compared to the 
area under the curve (Figure.19).  
 












The area under the curve is proportional to the antioxidant capacity as a small area indicates 
faster decay and less protection against the free radicals generated by AAPH. The area 
under the decay curve over time of the wine samples was calculated using Microsoft Excel 
and the concentration of trolox equivalents of antioxidant capacity in nmol/mL was 









y = 2074.8x + 5764 




























Trolox standard calibration curve 
Figure 19: The area under each curve was for each concentration trolox in nmol 




2 Testing the cardioprotective effect of synthetic wine  
2.1 Animals 
All experimental procedures were carried out with the approval of the faculty of Health 
Sciences Animal Ethics committee, University of Cape Town (Application 013/015 “Exploring 
the cardioprotective effect of synthetic wine using Long Evans rats”). All protocols were 
carried out in compliance with the guide for care and use of Laboratory Animals published by 
the U.S National Institute for Health (NIH publication No. 85(23), revised 1996). Male Long 
Evans rats (150-170g) were bred and obtained from the University of Cape Town animal 
unit. Animals were allowed access to food ad libitum but water or treatment was given 
according to body weight. The temperature was maintained at 22-24°C and lighting at 100-
300 lux. Rats were housed in a 12-hour light and dark cycle, with lights on at 06h00. 
2.2 Experimental design 
In order to assess the cardioprotective effect of synthetic wine with varying wine 
components, Long Evans rats were pre-treated with synthetic or water for a period of 14 
days. For this study, a total of 57 rats were divided into eight groups (Figure.20): Control 
(n=12), synthetic wine only (n=6), synthetic wine enriched with resveratrol only (n=7), 
synthetic wine enriched with melatonin only (n=7), synthetic wine enriched with both 
melatonin and resveratrol (n=6), water enriched with resveratrol only (n=5), water enriched 
with melatonin (n=8) and water enriched with both melatonin and resveratrol (n=6) .The 
treatment solutions were prepared by adding one part of synthetic wine or distilled water 
enriched with either resveratrol (100µg/L) or melatonin (75ng/L) (refer to Appendix F) to 
seven parts of drinking water as previously described (Lamont, Blackhurst et al. 2012). 
When the treatment was given to the rats, both body weight and the amount of drinking 
water consumed by each rat was taken into account to ensure that the amount given per day 
corresponded to an equivalent of 2 glasses of wine/day which would mimic the human 
setting. The rats were treated for a period of 14 days. On the 15th day, rats were 
anaesthetised, and ex vivo hemodynamic measurements were taken using the isolated 









Long Evans rats  
n=57 









































2.3 The Langendorff heart preparation as a model for the study of 
cardiovascular disease 
The isolated retrograde perfused mammalian heart system was first pioneered by Oscar 
Langendorff in 1895. The Langendorff system is a retrograde perfusion system which is 
frequently used in cardiac physiology to study cardiac metabolism, contractile function and 
coronary flow regulation.   
Before calibrating the Langendorff system, the apparatus was washed out with boiling 
distilled water several times to remove bacteria and debris. Once the apparatus was fully 
cleaned the Krebs Henseleit buffer (refer to Appendix D) was prepared. The molecular 
composition of the buffer resembles that of blood plasma in order to successfully perfuse the 
heart ex vivo.The Langendorff heart preparation entails the cannulation of the aorta which is 
then attached to a tank containing Krebs fluid oxygenated with 95% oxygen and 5% carbon 
dioxide. The oxygenated Krebs fluid is delivered in a retrograde direction down the aorta at a 
constant pressure maintained at 100cm with water. The aortic valves are forced shut and the 
perfusion fluid is directed into the coronary ostia, in that way perfusing the entire ventricular 
mass of the heart, draining into the right atrium via the coronary sinus. 
Figure 20: A schematic diagram showing the different treatment groups used to 





The general procedure for Langendorff perfusion entails excision of the heart from the donor 
anaesthesized animal. Immediately after excision, the heart is immersed in ice cold Krebs 
fluid before cannulation and vascular perfusion. A water-jacketed reservoir positioned above 
the aortic cannula, contains the Krebs fluid which is oxygenated through a sintered glass gas 
distributor. The aorta is then eased over the end of the cannula, taking precaution not to 
insert the cannula too far into the aorta.  Once the heart is securely attached to the cannula, 
any excess tissue is trimmed away. Once cannulation is completed and coronary perfusion 
is initiated, contractile function and regular heart rhythm will return within a few seconds. 
Throughout this time, various instrumentation is taken. Contractile activity of the heart, is 
assessed through insertion of a compliant intraventricular balloon. The balloon is inflated 
with water from a syringe until a left ventricle end diastolic pressure of between 4-12mm Hg 
is obtained. Once the balloon is in position, left ventricular systolic, diastolic and developed 
pressure can be recorded. Once instrumentation of the heart has been completed, a 
temperature regulated heart chamber should be placed around the heart to maintain the 
temperature at 37°C. 
2.4  Experimental Langendorff perfused isolated rat heart preparation. 
The Long Evans rats were anaesthetised with sodium pentobarbitone (60mg/kg) and heparin 
(200I.U.) intraperitoneally. Prior to anaesthesia, animals were placed in a quiet room for 15 
minutes to acclimatise them to the new environment. The depth of anaesthesia was judged 
by the absence of the pedal withdrawal reflex, whereby the paw of the rat was pinched and 
the perception of pain was observed. A thoracotomy was performed when the rat was 
deemed to have reached surgical anaesthesia. An incision of the skin below the sternum 
was delicately performed. The incision was continued along the proximal ends of the left and 
right costal margins. The thoracic cavity was opened and the pericardium surrounding the 
heart was removed, exposing the beating heart in the chest cavity. The heart was gently 
cradled and hoisted between the thumb and the index finger and removed with one quick 
precise cut without inflicting damage to the aorta. The isolated heart was immediately placed 
into ice-cold Krebs buffer [NaCl 118.5mM, NaHCO3 25mM, KCl 4.7mM, MgSO4.7H2O1.2mM, 
KH2PO4 1.2mM, Glucose 11.1mM, and CaCl2.2H2O1.3mM] as previously described (Krebs, 
Henseleit 1932) (for preparation and abbreviations refer to Appendix D). Blood was removed 
from the rat chest cavity and stored in a tube containing heparin (200 I.U). These tubes were 
centrifuged immediately at a speed of 2000g for 10 minutes to separate the plasma from the 





Subsequently, the heart was mounted retrogradely onto the cannula of the Langendorff 
apparatus within 3 minutes with two pairs of forceps stretching the aorta on either side to 




















This procedure was carried out under low flow to enable a fluid-fluid connection. The heart 
was temporarily secured with a bulldog clamp in order to keep it in place. Thereafter, a thin 
suture was tied around the aorta to secure the heart onto the cannula. The left ventricle was 
exposed with a small excision of the atrial appendage surrounding the left atria, to enable 
the insertion of a balloon. The intraventricular balloon was attached to a catheter filled with 
water which was connected to a pressure transducer (MLT0670, Lasec, South Africa) on a 
PowerLab system (ADInstruments, Australia) for hemodynamic measurements. Inside the 
left ventricle, the balloon was inflated by filling it with water, thus creating a closed system to 
measure the pressure experienced by the left ventricle.  
2.5  Experimental protocol 
All hearts were stabilized (S) for a period of 30 minutes and consequently subjected to 30 
minutes of global ischemia (GI) followed by 60 minutes of reperfusion (R) (Figure.22).  
Figure 21:  A Langendorff-perfused rat heart. Figure key: (a) intraventricular balloon 
inserted into the left ventricle and mounted on a 21-gauge bevelled needle; (b) 
thermal couple for continual temperature monitoring inserted in pulmonary artery; (c) 
cannula whereby heart is mounted onto system; (e) a 2-way tap placed between the 








Global ischemia was achieved by complete cessation of perfusate while reperfusion was  
restored by re-introducing perfusate. Temperature was measured with a thermocoupled wire 
(Physitemp, NJ, United States of America) inserted into the pulmonary artery, and connected 
to a Digitron 2600T temperature sensor (Torquay, United Kingdom)(Figure.23). Temperature 
was controlled at 37°C with a water jacket and a desk lamp. At the end of reperfusion, hearts 




2.6 Hemodynamic parameters 
Hemodynamic parameters were monitored throughout the experiments with LabChart Pro 7 
software (ADInstruments, Australia) and included heart rate (HR) expressed in beats/min , 
left ventricular developed pressure at mmHg (LVDP: difference between left ventricular end 
Figure 22:  A schematic representation of perfusion protocol 
14 days pre-treatment  
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systolic pressure (LVESP) and end diastolic pressure (LVEDP)) and the coronary flow (CF) 
expressed in ml/min. Functional recovery was assessed through the rate pressure product 
(RPP) which was calculated as LVDP X HR at the stabilisation period compared to the end 
of reperfusion. CF was measured with Falcon™ 15mL Conical Centrifuge Tubes. 
Functional parameters were measured at 5, 10, 20 and 30 minute intervals during the 
stabilisation period to ensure the inclusion criteria were met. 












2.7 Exclusion criteria    
Rats that did not meet the terms of the following criteria were not included in the study: 
A. The heart rate should fall between 240-360 beats/min 
B. The rate × pressure product must fall within the range 21 000-36 000 
C. Left ventricular end diastolic pressure of 2-12mm Hg 
D. The developed pressure should fall between 70-120mm Hg 
E. The coronary flow rate should be between 8-18 ml/min 
2.8 Infarct size 
Hearts were sectioned transversely at 2mm thickness and stained by immersion into 2,3,5-
Triphenyltetrazolium chloride solution (TTC) (1% in phosphate buffer) at pH 7.4 for 10 
minutes at 37ºC. TTC is a redox indicator used to differentiate between metabolically active 
Heart rate 
Systolic pressure  
Diastolic  pressure  
Left ventricular developed 
                 pressure  





and inactive tissue. TTC is a colourless solution which is enzymatically reduced to a brick 
red precipitation of formazan dye in living tissues with intact mitochondrial respiration due to 
the activity of various dehydrogenases in the presence of the electron donor NADH. After 
TTC staining, necrotic zones remain as pale areas of the heart as a result of enzymatic 
wash-out in damaged cells. The slices were then fixed in 10% formalin for 24 hours and 
scanned using a flatbed scanner. Infarct size was quantified by with both computerised 
planimetry (Summa sketch II; Summa Graphics) and Image J (National Institute of Health, 
United States of America). 
 
3 Analysis of  total antioxidant capacity of blood plasma 
There is strong evidence to suggest that increased intracellular ROS are a central cause of 
myocardial injury. The changes associated with myocardial injury result, in part in an 
imbalance between the formation of oxidants and the availability of endogenous 
antioxidants. Experiments were performed using the ORAC, thiobarbitituric acid reactive 
substances (TBARS), catalase and superoxide dismutase assay to measure the total 
antioxidant capabilities and levels of oxidative stress in plasma from animals that received 
different treatments for 14 days.  
3.1  Protein quantification  
The Lowry Assay was used to quantify the concentration of plasma proteins (Lowry, 
Rosebrough et al. 1951). A series of dilutions of 0.3mg/ml bovine serum albumin was 
prepared to create a standard curve with concentrations which ranged from 0.03 to 
1.15mg/ml. A volume of 200µL of sample or standard was added to 1ml of freshly mixed 
complex-forming reagent, subsequently the solution was left to stand at room temperature 
for 10 minutes. Afterwards, 100µL of diluted folin reagent was added. The mixture was left to 
stand at room temperature for a further 30 minutes. The absorbance was read at 750nm for 
protein concentration below 500ug/mL or at 550nm if the protein concentration was between 
100µg/ml and 2000 µg/ml. 
The standard curve of absorbance as a function of initial protein concentration was used to 








3.2   Sample preparation: protein extraction 
Plasma samples were thawed slowly and mixed well on a vortex. To extract the protein from 
the plasma, 200μl ice cold ethanol (100%) was added to 100μl of plasma. The mixture was 
then centrifuged at 12000 rpm at 4°C for 5 minutes. The protein free supernatant was diluted 
363x in the phosphate buffer (Refer to Appendix E). Plasma antioxidant capacity was 
determined by ORAC assay using deproteinized plasma using the same method as 
previously described in section 1.3 of this chapter. 
 
 
3.3 Thiobarbituric acid reactive substances (TBARS) assay 
The thiobarbituric acid reactive substances (TBARS) are formed as part of lipid peroxidation 
and may be detected using thiobarbituric acid (TBA) as a reagent. The assay mostly 
measures malondialdehyde (MDA) in the plasma, a low molecular weight end product of lipid 
peroxidation of polyunsaturated fatty acids. MDA and other TBARS in the plasma condense 
with two equivalents of thiobarbituric acid to give a red derivative that can be assayed 
spectrophotometrically. In order to measure the amount of MDA in the rat plasma, the 
TBARS assay was performed according to the method of (Jentzsch, Bachmann et al. 
1996)Jentzsch (Jentzsch, Bachmann et al. 1996).  
Plasma was mixed with butylated hydroxytoluene (BHT) and 50µL orthophosphoric acid in 
2mL Eppendorf micro test tubes and vortexed for 10 seconds. 25µL TBA reagent was added 
and the mixture was vortexed again. The reaction mixture was then heated at 90ºC for 45 
minutes. The tubes were put on ice to stop the reaction. After cooling to room temperature 
for 5 minutes, TBARS were extracted once with 500µL n-butanol. To facilitate phase 
separation, 50µl saturated sodium chloride solution was added, and the test tubes were 
centrifuged at 2000 rpm for 2 minutes in a centrifuge. 300µL of the upper butanol phase was 
placed in a flat-bottom 96-well plate. Absorption was read at 535nm on a spectrophotometer 
(Spectramax Plus 384, Molecular Devices, Labotec, South Africa) using Softmax Pro 
(Version 4.4) software 
 
3.4 Catalase activity assay 
The catalase activity assay is based on the principle that catalase, an antioxidant enzyme, 
catalyses the reduction of hydrogen peroxide to water (Aebi 1984) and (Claiborne 1985).  




150µL of hydrogen peroxide to 100mL of phosphate buffer. The phosphate buffer was 
prepared by adding KH2PO4(50mM) to Na2HPO4(50mM) to a final volume of one litre and 
concentration of 50mM (ph 7.0). All the samples were diluted to a ratio of one in ten. 241µL 
of phosphate buffer was added into the first two wells and 241µL of the hydrogen peroxide 
was added to the next two wells. In the remainder of the wells, 10µL of the diluted samples 
was added as well as 10µL of phosphate buffer. 
The 96-well plate (Co-star,Lasec,SA) was inserted into the spectrophotometer (Spectramax 
Plus 384, Molecular Devices, Labotec, South Africa) and a reading was recorded at 240nm 
to confirm that the optical density of the diluted hydrogen peroxide was approximately 
0.52±0.025. Thereafter, 221µL of the diluted hydrogen peroxide was added to each well and 
the timer was started. A reading was recorded (at time point zero) and exactly one minute 
later another reading was taken. The zero minute reading was subtracted from the one 
minute reading. The difference between these two values was used to calculate the final 
catalase activity which was expressed as international units per milligram protein. 
 
 
3.5 Superoxide dismutase (SOD) activity assay  
Plasma superoxide dismutase (SOD) activity was measured by using a method adapted 
from ((Dalloz, Maingon et al. 1999). The first step was to prepare all components of the 
assay including the phosphate buffer (50mM), xanthine (2mM), ammonium sulphate (3mM), 
superoxide dismutase (stock solutions for the purpose of the standard curve )(5000IU/mL), 
xanthine oxidase solution and the reaction solution. The second step was to determine the 
reaction slope of the xanthine oxidase solution, during which the volume of xanthine oxidase 
was either decreased or increased to bring the reaction slope to approximately 0.025±0.027. 
To do this, 290µL of the reaction solution was added to wells A1 and A2 of a Greiner 96-well 
plate, together with 6µL of phosphate buffer. Lastly, 3.5µL of xanthine oxidase was added 
and the timer was started. Absorbance was read using a spectrometer (preheated to 37ºC) 
at 550nm, with a micro plate data acquisition program  Softmax Pro (Version 4.4) software.  
This was considered the reading at time point zero and after exactly three minutes, another 
reading was recorded. The reaction slope of the xanthine oxidase was then calculated by 
subtracting the first reading from the last. Once this slope was adjusted to approximately 
0.025±0.027, the rest of the assay was performed. 
The third step was to prepare the range of SOD dilutions in order to generate the SOD 




(0µL SOD in 5mL phosphate buffer), 10IU/mL (10µL SOD in 4990µL phosphate buffer), 20 
IU/mL (20µL SOD in 4980µL), 40IU/mL (40µL SOD in 4960µL phosphate buffer), 80IU/mL 
(80 µL SOD in 4920µL phosphate buffer). In a clean 96 well plate, 3.5 µL of each standard 
was pipette into wells A1 to A10 in a duplicate manner. In these wells 290 µL of reaction 
solution was also added as well as 6 µL of phosphate buffer. During the fourth step of the 
assay, 3.8 µL of each blood plasma sample was added to the separate well. After all the 
additions were made, 3.5µL of xanthine oxidase was added to all the wells containing the 
SOD and a reading was taken using a spectrophotometer. A reading was recorded at time 
point zero with a micro plate data acquisition program and exactly three minutes later 
another reading was recorded. The final reaction slope was determined and the final plasma 
SOD activity was expressed in international units per milligram protein 
 
 
4. Statistical analysis 
All values were presented as mean ± standard error mean (SEM). Column statistics were 
done to confirm if the data passed normal distribution with the Shapiro-Wilk normality tests. 
For comparison of more than two groups, data were analysed by one-way analysis of 
variance (ANOVA), followed by a Tukey-Kramer post hoc comparison using GraphPad 
Prism 3.0. Differences within the data were considered statistically significant when P < 0.05. 
 
5. Chemical agents 

























































1. Determination of stability of synthetic wine over 20 weeks 
 
  
The concentration of phenolic compounds and total antioxidant capacity was 
determined over the course of 20 weeks in order to assess the stability of the 
synthetic wine. Phenols are effective radical scavengers, during lipid, protein and 
DNA oxidation. In addition, phenolic compounds may act as secondary antioxidants. 
Rather than scavenging free radicals themselves, they are able to regenerate 
antioxidants vitamins E and/or C when they accept or donate electrons from a free 
radical. It was therefore important to analyse the stability of the antioxidant 
functionality of the synthetic wine during the course of the project. 
 
1.1 Determination of the total phenol content in synthetic   
wine  
 
The concentration of total phenolic compounds of the synthetic wine was determined 
using the Folin-Ciocalteu method at 4 different time points of storage over 20 weeks 
(Figure. 25). Results showed no statistically significant difference between the 4 time 
points. The values were determined from a regression equation calibration curve for 
each week and were expressed in gallic acid equivalents (GAE) per volume of wine. 
The total phenol concentration ranged from 40.0±3.1 to 53.0±7.0 mg/mL GAE.  


















Figure 25: The total phenol content in synthetic wine over a period of 20 weeks. n=3 







1.2 Determination of the total antioxidant capacity of synthetic  
wine 
 
The total antioxidant capacity of the synthetic wine was assessed using the ORAC 
assay. The ORAC values of the synthetic wine at 4 different time points over 20 
weeks ranged from 8.9±0.1 to 10.7±0.4 µmol/mL Trolox equivalents (TE) 
(Figure.26). There were no statistically significant differences in the total antioxidant 
capacity between the 4 time points of storage. The intra- assay coefficient of 

























1.3 Determination of the total antioxidant capacity of synthetic 
wine enriched with resveratrol and/or melatonin 
 
The total antioxidant capacity of both water and synthetic wine enriched with 
melatonin and/or resveratrol was determined in order to assess functionality before 
feeding to animals. The ORAC values ranged from 9.2±0.7 to 15.5±1.9 µmol/mL 
Trolox antioxidant equivalents (TE) (Figure.27). There was significant difference in 











Figure 27: The total antioxidant capacity of synthetic wine and water enriched with melatonin (Mel) and 
Resveratrol (Resv) n=2 Mel- Melatonin Resv-Resveratrol SW-Synthetic wine *p<0.05 vs. Water, **p<0.01 vs. 
















2. Effect of synthetic wine enriched with melatonin and/or resveratrol in 
isolated hearts subjected to an ischemia/reperfusion insult 
 
 2.1 Effect of chronic consumption of synthetic wine with melatonin and/or 
resveratrol on heart rate  
 
Prior to an ischemic insult, control hearts had a heart rate of 278±8 beats/min (Table 2). This 
is consistent with findings previously described in the literature (Lecour, Smith et al. 2002). 
Pre-treatment with melatonin or resveratrol with and without synthetic wine had no significant 
effect on the pre-ischemic values of heart rate compared to the control group.  After 30 
minutes of ischemia and 60 minutes of reperfusion, the control hearts had a heart rate of 
256±15 beats/min (p>0.05 vs. pre-ischemia). None of the treatments affected the heart rate 
at the end of reperfusion compared to the control group. 
 
 
Table 2: Effect of chronic consumption of synthetic wine with melatonin and/or resveratrol on 














Water (Control) 278± 8 242 ± 44 250± 36 303± 42 308± 57 256± 15 
Water & melatonin 276± 12 131 ± 26 146± 35 288± 20 300± 15 301± 12 
Water & 
resveratrol 
292± 17 214 ± 95 309± 81 326± 34 337± 41 280± 12 
Water, resveratrol 
& melatonin 
276± 17 151 ± 49 241± 39 242± 41 262± 45 269± 20 
Synthetic wine 270± 7 162 ± 52 179± 40 174± 20 221± 22 228± 19 
Synthetic wine & 
melatonin 
266± 7 220 ± 57 127± 29 234± 34 225± 17 208± 43 
Synthetic wine & 
resveratrol 




281± 14 144 ± 38 234± 25 255± 35 263± 27 276± 17 
Control n=12, Synthetic wine n=6, SW & M-synthetic wine & Melatonin n=7 wine, SW & R-synthetic wine & Resveratrol n=7, W 
& M-Water & Melatonin n=8, W & R-Water & Resveratrol n=5, W,M & R-Water,Melatonin & Resveratrol n=6, SW, M & R-










2.2 Effect of chronic consumption of synthetic wine enriched with melatonin 
and/or resveratrol on left ventricular developed pressure (LVDP) in hearts 
subjected to ischemia/reperfusion injury 
 
At baseline, control hearts had a LVDP of 88±2 mmHg (Table 3). Pre-treatment with 
melatonin or resveratrol with and without synthetic wine had no significant effect on the pre-
ischemic LVDP values compared to the control group. After 30 minutes of ischemia and 60 
minutes of reperfusion, the control hearts had a LVDP of 12±2 mmHg (#p<0.05 vs. pre-
ischemia). After 60 minutes of reperfusion, pre-treatment with synthetic wine did not improve 
the LVDP compared to controls. Addition of melatonin or resveratrol in the synthetic wine did 
not alter the LVDP. Pre-treatment with melatonin or resveratrol without synthetic wine did not 
display a significant improvement in the LVDP compared to the untreated controls. After 30, 
45 and 60 minutes of reperfusion, pre-treatment with synthetic wine enriched with both 
resveratrol and melatonin improved LVDP to 24±5mmHg, 30±5mmHg and 29±5mmHg 
respectively, (*p<0.05 vs. control.). After 45minutes of reperfusion, water enriched with both 
resveratrol and melatonin significantly improved LVDP to 31± 8mmHg (*p<0.05 vs. control) 
however, this effect was lost at 60 minutes. 
 
Table 3: Effect of chronic consumption of synthetic wine or water enriched with melatonin 
and/or resveratrol on LVDP (mmHg) in isolated rat hearts subjected to ischemia/reperfusion 
injury 










Water(Control) 88± 2 2± 1 6± 2 6± 2 10± 3 12± 2# 
Synthetic wine 94± 6 9± 4 9± 2 13± 5 14± 5 15± 5# 
Synthetic wine & 
melatonin 
82± 2  2± 1 2± 1 6± 1 9± 2 10± 2# 
Synthetic wine & 
resveratrol 




88± 4 4± 2 8± 4 24± 5* 30± 5* 29± 5*# 
Water & 
melatonin 
79± 5   4± 1 4± 2 11± 4 18± 4 20± 4# 
Water & 
resveratrol 




88± 4 3± 2 6± 3 20± 6 31± 8* 28± 7# 
Control n=12, Synthetic wine n=6, SW & M-synthetic wine & Melatonin n=7 wine, SW & R-synthetic wine & Resveratrol n=7, W 
& M-Water & Melatonin n=8, W & R-Water & Resveratrol n=5, W,M & R-Water,Melatonin & Resveratrol n=6, SW, M & R-
Synthetic wine, melatonin and Resveratrol n=6. 
*p<0.05 vs. the control group at same time of reperfusion 





2.3 Effect of chronic consumption of synthetic wine enriched with melatonin 
and/or resveratrol on functional recovery in hearts subjected to 
ischemia/reperfusion injury 
 
After 60min of reperfusion the control hearts had a functional recovery of 11±2% (which is 
expressed as a percentage of baseline).The pre-treatment with resveratrol significantly 
enhanced the functional recovery compared with control groups (*p <0.05) and protected to 
a similar degree to animals pre-treated with melatonin only (25±3% vs. 26±5%). Synthetic 
wine alone did not significantly improve the functional recovery after 60 minutes of 
reperfusion compared with controls (15±6% vs. control). Addition of either melatonin or 
resveratrol in the synthetic wine did not significantly improve the functional recovery 
compared to the untreated control hearts. Pre-treatment with synthetic wine enriched with 
both resveratrol and melatonin enhanced the functional recovery compared with control 
groups (**p<0.01) and protected to a similar degree to water enriched with both resveratrol 








Figure 28: Effect of chronic consumption of synthetic wine enriched with melatonin(Mel) and/or 
Resveratrol(Resv) on functional recovery after 60 minutes of reperfusion. Control n=12, Synthetic wine n=6, 
SW & M-synthetic wine & Melatonin n=7 wine, SW & R-synthetic wine & Resveratrol n=7, W & M-Water & 
Melatonin n=8, W & R-Water & Resveratrol n=5, W,M & R-Water,Melatonin & Resveratrol n=6, SW, M & R-
Synthetic wine, melatonin and Resveratrol n=6. *p<0.05 vs. control  **p<0.01 vs. Control $p<0.05 vs. Water or 










2.4 Effect of chronic consumption of synthetic wine or water enriched with 
melatonin and/or resveratrol on coronary flow in hearts subjected to 
ischemia/reperfusion injury 
 
At baseline, control hearts had a coronary flow of 12.0 ±1.2 mL/min (Table 4). This is 
consistent with findings previously described in the literature (Lecour, Smith et al. 2002). 
Pre-treatment with synthetic wine or water with/ without melatonin and/or resveratrol had no 
significant effect on the pre-ischemic values of coronary flow compared to the control group. 
After 30 minutes of ischemia and 60 minutes of reperfusion the control hearts had a 
coronary flow of 6.4±0.5 mL/min (p<0.05 vs. pre-ischemia) none of the treatments affected 
coronary flow at the end of reperfusion compared to the control group. 
 
Table 4: Effect of chronic consumption of synthetic wine enriched with melatonin and/or 















Water(Control) 12.3± 1.2 5.0± 0.7 6.3± 0.7 5.1± 0.6 6.1± 0.5 6.1± 0.5# 
Synthetic wine 12.1± 0.1 5.2± 0.5 5.2± 0.7 5.4± 0.7 6.3± 0.8 6.1± 0.6# 
Synthetic wine & 
melatonin 
13.6± 0.6 6.4± 0.5 6.0± 0.5 7.0± 0.4 7.1± 0.5 7.3± 0.3# 
Synthetic wine & 
resveratrol 




14.4± 1.1 3.3± 0.8 5.5± 0.9 7.4±0.2 7.2±0.3 7.4± 0.2# 
Water & 
melatonin 
13.3± 1.2 6.3± 1.0 7.1± 1.0 7.3± 0.8 7.0± 0.9 7.1± 0.8# 
Water & 
resveratrol 
14.7± 1.7 4.4± 0.5 6.3± 0.7 7.1± 0.5 7.4± 0.5 7.2± 0.5# 
Water, resveratrol 
& melatonin 
13.1± 0.9 4.2± 0.1 6.4± 0.2 7.1±0.5 7.3±0.7 7.1±0.5# 
#p<0.05 60 minutes of reperfusion vs. pre ischemia 
Control n=12, Synthetic wine n=6, SW & M-synthetic wine & Melatonin n=7 wine, SW & R-synthetic 
wine & Resveratrol n=7, W & M-Water & Melatonin n=8, W & R-Water & Resveratrol n=5, W,M & R-









2.5 Effect of chronic consumption of synthetic wine enriched with melatonin 
and/or resveratrol on infarct size  
 
In order to quantify the total infarct area, two different forms of computerised planimetry were 
used namely Image J (NIH) and a digitizing tablet (SummaSketch graphics). The analysis 
was performed by a researcher blinded to the treatments. 
 
2.5.1 Infarct size measured with IMAGE J analysis 
The control hearts subjected to 30 min global ischemia followed by 60 min of reperfusion 
had an infarct size of 49.2±4.7%. Pre-treatment with synthetic wine did not reduce infarct 
size compared to controls (44.0±8.0% vs. control). None of the treatment combinations 












Figure 29: Effect of chronic consumption of synthetic wine enriched with melatonin(Mel) and/or Resveratrol(Resv) 
on infarct size after 60 minutes of reperfusion using Image J. Control n=12, Synthetic wine n=6, SW & M-synthetic wine 
& Melatonin n=7 wine, SW & R-synthetic wine & Resveratrol n=7, W & M-Water & Melatonin n=8, W & R-Water & 










2.5.2 Infarct size measured with digitized tablet (SummaSketch graphics) 
The control hearts subjected to 30 min global ischemia followed by 60 min of 
reperfusion had an infarct size of 61.2±4.0% using a digitized tablet. Pre-treatment 
with synthetic wine did not reduce infarct size compared to controls (53.4±8.0% vs 
control). None of the treatment combinations significantly reduced the infarct size 















Figure 30: Effect of chronic consumption of synthetic wine enriched with melatonin(Mel) and/or 
Resveratrol(Resv) on infarct size after 60 minutes of reperfusion using a digitized tablet. Control n=12, 
Synthetic wine n=6, SW & M-synthetic wine & Melatonin n=7 wine, SW & R-synthetic wine & Resveratrol n=7, W & M-
Water & Melatonin n=8, W & R-Water & Resveratrol n=5, W,M & R-Water,Melatonin & Resveratrol n=6, SW, M & R-













3. Analysis of the antioxidant effect of synthetic wine with and without 
melatonin and Resveratrol on rat plasma antioxidant activity  
3.1 Effect of chronic consumption of synthetic wine enriched with 
melatonin and/or resveratrol on plasma total antioxidant activity  
 
The total antioxidant capacity of the rat plasma after various treatments was assessed by 
using the ORAC assay (Figure.31). Control animals had a total antioxidant capacity of 
9.4±2.2 μmol/mL trolox equivalents (TE). There was no difference between animals pre-
treated with synthetic wine compared to the control group (15.2±3.6 μmol/mL vs control). 
Synthetic wine enriched with either melatonin or resveratrol did not alter the total antioxidant 
activity relative to the control group. The ORAC values did not differ between animals pre-
treated with water enriched with melatonin (7.7±2.5 μmol/mL) and water enriched with 
resveratrol (6.5±2.4 μmol/mL). However, animals pre-treated with synthetic wine and water 
enriched with both resveratrol and melatonin demonstrated a significant reduction in total 
antioxidant capacity relative to animals treated with synthetic wine only (**p<0.01;1.1±2.9 
mol/mL, 1.0±0.4 μmol/mL vs synthetic wine). Similarly, animals pre-treated with synthetic 
wine and water enriched with both resveratrol and melatonin showed a significant reduction 
in total antioxidant capacity relative to animals treated with synthetic wine enriched with 





Figure 31: Oxygen radical absorbance capacity (ORAC) assay to determine the plasma antioxidant capacity in Trolox 
equivalents (µmol/mL). Mel-Melatonin and Resv-Resveratrol.**p<0.01 vs. Synthetic wine, ***p<0.001 vs. Synthetic 
wine enriched with both resveratrol and melatonin/Water enriched with  both resveratrol and melatonin. Control n=12, 
Synthetic wine n=6, SW & M-synthetic wine & Melatonin n=7 wine, SW & R-synthetic wine & Resveratrol n=7, W & M-
Water & Melatonin n=8, W & R-Water & Resveratrol n=5, W,M & R-Water,Melatonin & Resveratrol n=6, SW, M & R-








3.2 Effect of chronic consumption of synthetic wine enriched with 
melatonin and/or resveratrol on plasma levels of oxidative stress 
markers 
 
To measure markers of oxidative stress in the plasma after various treatments, a marker of 
lipid peroxidation, the TBARS assay measuring plasma MDA concentrations was carried out. 
Water treated animals had a MDA concentration of 11.5±1.1 μmol/L (Figure.32). There was 
no significant difference between animals pre-treated with synthetic wine compared to the 
control group (12.6±2.2 μmol/L vs control). Addition of either melatonin or resveratrol in the 
synthetic wine did not significantly alter MDA levels relative to the control group (8.5±0.4 
μmol/L & 11.7±1.6μmol/L, respectively). Furthermore, the MDA concentrations did not 
significantly differ between animals treated with water enriched with melatonin (9.8±0.9 
μmol/L) and water enriched with resveratrol alone (9.76±0.69 μmol/L). Animals pre-treated 
with synthetic wine combined with both resveratrol and melatonin displayed significantly 
higher MDA concentrations relative to animals treated with synthetic wine and melatonin 
only (16.3±0.9 μmol/L vs synthetic wine and melatonin). In addition, animals treated with 
water combined with resveratrol and melatonin showed significantly increased MDA 
concentrations compared to animals treated with synthetic wine enriched with melatonin 





Figure 32: Results of Thiobarbituric acid reactive substances assay (TBARS) assay for the measurement of 
malondialdehyde (MDA) in rat plasma. Mel-Melatonin and Resv-Resveratrol. #p<0.01 vs. Synthetic wine and melatonin. 
Control n=12, Synthetic wine n=6, SW & M-synthetic wine & Melatonin n=7 wine, SW & R-synthetic wine & Resveratrol 
n=7, W & M-Water & Melatonin n=8, W & R-Water & Resveratrol n=5, W,M & R-Water,Melatonin & Resveratrol n=6, SW, 







3.3 Effect of chronic consumption of synthetic wine or water enriched 
with/without melatonin and/or resveratrol on plasma antioxidant enzyme 
catalase activity 
 
Catalase activity of the plasma obtained from various treatment groups was assessed. 
Results shown in Figure 32 illustrate control animals had a total catalase activity of 
39.89±9.47 IU/mg protein. There was no statistically significant difference between animals 
pre-treated with synthetic wine compared to the group treated with water only (25.5±11.5 
IU/mg protein vs control). Addition of melatonin or resveratrol in the synthetic wine did not 
significantly alter catalase activity relative to the control group (28.7±5.3 IU/mg protein & 
36.9±8.3IU/mg protein, respectively). Furthermore, the catalase activity did not differ 
between animals treated with melatonin alone (29.2±7.2 IU/mg protein) and resveratrol 
alone (24.7±6.6 IU/mg protein). Synthetic wine or water enriched with melatonin and 










Figure 32: Effect of chronic consumption of synthetic wine or water enriched with/without melatonin(Mel) and/or 
Resveratrol(Resv) on Catalase activity in rat plasma. Control n=12, Synthetic wine n=6, SW & M-synthetic wine & 
Melatonin n=7 wine, SW & R-synthetic wine & Resveratrol n=7, W & M-Water & Melatonin n=8, W & R-Water & 










3.4 Effect of chronic consumption of synthetic wine or water enriched 
with/without melatonin and/or resveratrol on plasma antioxidant enzyme 
superoxide dismutase (SOD) activity 
 
SOD activity of the plasma obtained from various treatment groups was assessed. Results 
shown in Figure.33 illustrate control animals had a total SOD activity of 6.6±0.8 IU/mg 
protein. There was no statistically significant difference between animals pre-treated with 
synthetic wine compared to the control group (7.4±0.5 IU/mg protein vs control). Addition of 
melatonin or resveratrol in the synthetic wine did not significantly alter SOD activity relative 
to the control group (6.0±0.3 IU/mg protein & 6.2±0.7 IU/mg protein, respectively). 
Furthermore, SOD activity did not differ between animals treated with melatonin alone 
(7.7±0.4 IU/mg protein) and resveratrol alone (7.0±0.3 IU/mg protein). Synthetic wine or 
water enriched with both melatonin and resveratrol did not significantly change the SOD 










Figure 33: Effect of chronic consumption of synthetic wine or water enriched with/without melatonin (Mel) and/or 
Resveratrol (Resv) on superoxide dismutase activity in rat plasma. Control n=12, Synthetic wine n=6, SW & M-
synthetic wine & Melatonin n=7 wine, SW & R-synthetic wine & Resveratrol n=7, W & M-Water & Melatonin n=8, W & 






















































4.1 Summary of results 
The aim of our study was to use synthetic wine whose composition is well characterized to 
explore whether the presence of alcohol, resveratrol and melatonin (as found in commercial 
wine) contributes to the cardioprotective effect of chronic and moderate (2 glasses wine/day) 
consumption of red wine in an animal model. Additionally, we hypothesized that synthetic 
wine enriched with these components confers cardioprotection via improvement of overall 
antioxidant profile. 
 
In this study, we have confirmed that chronic and moderate consumption of resveratrol or 
melatonin, given in water for 14 days, has the ability to protect the heart against IR injury in 
an animal model. Synthetic wine, given on its own for 14 days, did not confer any 
cardioprotective benefit. However, a chronic treatment of synthetic wine enriched with both 
resveratrol and melatonin conferred cardioprotection against IR injury. Surprisingly, this 
cardioprotective effect was lost when the synthetic wine was given with resveratrol or 
melatonin only.  
A chronic treatment with synthetic wine enriched with both melatonin and resveratrol did not 
affect plasma antioxidant enzymes activities and plasma lipid peroxidation in rats. These 
data therefore do not support that red wine protects via a modulation of the antioxidant 
profile.   
Our data therefore suggest that the presence of both melatonin and resveratrol is critical for 

















4.2 Stability of synthetic wine 
A synthetic wine is traditionally used in wine biotechnology to optimize yeast fermentations 
and to assess the efficiency of various yeast strains. To the best of our knowledge, this is the 
first study to use synthetic wine in order to investigate its effect against IR injury. Since there 
was virtually no information available on the chemical and functional properties of the 
synthetic wine, the first objective of our study was to investigate synthetic wines stability and 
functionality before feeding it to our animals. The total antioxidant capacity and total phenol 
of the synthetic wine remained relatively the same throughout the 20 week storage period. 
These measures therefore suggest that the synthetic wines chemical and functional 
properties remain constant throughout the duration of the project and this information was 
useful to avoid any confounders due to artefacts of ageing in the wine. 
4.3 Cardioprotection with synthetic wine  
4.3.1 Alcohol fails to induce cardioprotection  
 
Alcohol is thought to contribute to the cardioprotective effect of red wine against IR injury. In 
this study, we were able to demonstrate that synthetic wine, an alcohol based matrix, did not 
confer protection against IR injury. This result suggests that alcohol solely does not play a 
vital role in wine induced cardioprotection.  
Previous studies have demonstrated that protection conferred by alcohol against IR injury 
proceeds through an ischemic preconditioning-like mechanism which involves activation of 
protein kinase C (PKC) and that this is dependent on the time and duration of ethanol 
exposure. Hence, a study has shown that rats treated with 36% alcohol for 16 weeks and 
ginea pigs treated with 20 % alcohol for 16 weeks protected the hearts against IR injury 
(Miyamae, Camacho et al. 1998). Likewise, guinea pigs fed with 2.5% alcohol for four 
months showed improved recovery of post-ischemic left ventricular developed pressure and 
decreased necrosis compared to control ginea pigs fed with water (Miyamae, Domae et al. 
2003). In contrast, in our study the chronic consumption of synthetic wine (12%) for 14 days 
did not improve functional recovery nor reduce infarct size.  Possibly, if the rats were pre-
treated for a longer duration or given the treatments through oral gavage, cardioproection 




established planimetry techniques, Image J and Summa sketch. Both techniques showed 
similar patterns in measuring the level of necrosis in the heart tissue. However, Image J 
computerised planimetry in our opinion, is more objective relative to Summa sketch since it 
detects infarct size based on threshold settings predetermined by the program. In contrast,  
Summa sketch detection of infarct size is dependent on the skill of the person analysing the 
hearts. 
 
4.3.2 Resveratrol protects isolated hearts against 
ischemia/reperfusion injury 
Substantial experimental evidence has demonstrated that acute administration of resveratrol 
can provide cardioprotection against IR injury. Resveratrol given at a concentration of 
228µg/L  elicits its cardioprotective effect by improving post-ischemic ventricular function and 
aortic flow, reduces infarct size and translocates glycogen synthase kinase 3 β (GSK-3 β) 
from the cytosol to the mitochondria presumably by targeting the mitochondria permeability 
transition pore (mPTP)(Xi, Wang et al. 2009) (Ray, Maulik et al. 1999a). However, most 
studies administered resveratrol at a much higher concentration than that found in wine. 
Lamont and colleagues were able to observe a cardioprotective effect when resveratrol 
(2.3mg/L) was given acutely to hearts exposed to IR injury. Furthermore, resveratrol was 
shown to protect through the activation of the SAFE pathway (Lamont, Somers et al. 2011). 
However, when rats were pre-treated with resveratrol (7mg/L) chronically for 10 days, 
Resveratrol failed to improve post-ischemic functional recovery or reduced infarct size 
(Lamont 2009b). 
To date, there have not been any studies that explored the cardioprotective effect of chronic 
administration of resveratrol against IR injury. To the best of our knowledge, our study is the 
first to demonstrate that the chronic consumption of resveratrol at a concentration of 100µg/L 
can protect against IR injury. We observed that hearts pre-treated with resveratrol 
independent of synthetic wine showed improved functional recovery after IR insults. 
However, our antioxidant and oxidative stress data do not show significant differences 
between resveratrol and other treatment groups, suggesting that resveratrol might elicit its 
cardioprotective effects independent of its’ direct radical scavenging effect. Treatment of 
normal rats with resveratrol does not affect lipid peroxidation, as reflected by the presence of 
TBARS (Turrens, Lariccia et al. 1997). However, in spontaneously hypertensive rats, pre-
treatment with resveratrol (2.3mg/body weight) for 8 weeks significantly reduced oxidative 




supplemented with resveratrol for 2 months had a higher survival rate than their control 
counterparts after isoproterenol injection (60 mg/kg) and this effect was largely associated 
with increased antioxidant enzyme activities and reduced oxidative damage (Avila, Marques 
et al. 2013). These studies show that resveratrol can suppress pathological increases in the 
peroxidation of lipids and other macromolecules in vivo. However, it is possible that 
resveratrol exerts its cardioprotective effect through NO and adenosine. Indeed, in a similar 
model to ours, rats provided with resveratrol (1mg/body weight) for 15 days showed 
improved recovery in function and coronary flow of isolated hearts even 24 hours after 
resveratrol treatment was stopped (Bradamante, Barenghi et al. 2003). This protective effect 
was hindered by L-NAME, a nitric oxide synthase (NOS) inhibitor or 8-(p-
sulfophenyl)theophylline (SPT), an adenosine receptor antagonist. This could possibly 
suggest that the activation of adenosine receptors play a role in the delayed effects of 
resveratrol. Surprisingly, the addition of resveratrol in synthetic wine did not improve post-
ischemic left ventricular function. This could be due, in part, to a quenching effect of the 
synthetic wine, however, more studies would have to be done in examining interactions 
between properties of synthetic wine. 
 
4.3.3 Melatonin protects isolated heart against 
ischemia/reperfusion injury 
Previous studies have shown that melatonin administered both chronically and acutely 
reduced myocardial IR injury in an isolated heart model. Indeed, isolated hearts exposed to 
an acute concentration (100µM) of melatonin demonstrated a significant reduction in MDA, 
improve left ventricular function and decreased duration of ventricular tachycardia and 
ventricular fibrillation (Kaneko, Okumura et al. 2000). In an in vivo model, rats exposed to IR 
injury and treated with melatonin (10mg/kg) before ischemia showed a significant reduction 
in MDA levels, infarct size and increased glutathione (GSH) levels (Sahna, Parlakpinar et al. 
2005). However, the concentration of melatonin used in these studies is much higher than 
the concentration found in red wine, which usually ranges between 74ng/mL to 423 ng/mL 
subject to the grape variety (Rodriguez-Naranjo, Gil-Izquierdo et al. 2011b). 
In our experiments, chronic consumption of melatonin given alone at a concentration of 
75ng/L was sufficient to improve functional recovery as previously described size (Lamont 
2009b). However, the treatment failed to reduce infarct size. Previous studies in our lab have 
demonstrated a reduction in infarct size after pre-treated with melatonin (75ng/L) for 10 days 




after 14 days of pre-treatment. This could be attributed to the levels of stress the rats were 
exposed to at the time of these experiments as the building in which the rats were housed 
was undergoing extensive renovations and the noise may have significantly altered the 
behaviours of the experimental subjects. In addition, our oxidative stress and antioxidant 
data does not show significant differences between melatonin and the control group, thus  
suggesting that the free radical scavenging properties of melatonin may not play a major role 
in its cardioprotective effect in our model. It is possible melatonin conferred its effect through 
melatonin receptors. Previously, it has been shown that melatonin mediates its 
cardioprotective effect by activating pro-survival RISK and SAFE pathways during 
reperfusion and inhibiting the opening of the MPTP (Smith, Dixon et al. 2010). Lamont and 
colleagues demonstrated convincingly the significance of melatonin receptors in melatonin 
induced cardioprotective by demonstrating that luzindole, selective melatonin receptor 




4.3.4 Combination of resveratrol and melatonin induces additional 
cardioprotection  
Red wine has been shown to be cardioprotective against IR injury. Multiple studies have 
demonstrated the protective effect of red wine using red wine extracts, singular components 
of red wine such as resveratrol or ethanol (Sato, Ray et al. 2000) or whole red wine (Lamont, 
Blackhurst et al. 2012, Lamont 2009). A previous study in our lab surprisingly demonstrated 
an inverse relationship between resveratrol and melatonin content i.e South African wines 
with high melatonin content had a low resveratrol content and conversely (Albertyn 2012). 
Nonetheless, wines which displayed this relationship showed improved functional 
parameters after IR injury. This demonstrates melatonin and resveratrol in wine may act 
synergistically to provide a cardioprotective effect against IR injury. One of the chief 
limitations of this study was that it was difficult to attribute the cardioprotection to melatonin 
specifically as wine is a complex matrix with multiple components which may be responsible 
for wine-induced cardioprotection. 
In our experiments, a chronic pre-treatment of synthetic wine enriched with both melatonin 
and resveratrol at concentrations 75ng/L and 100µg/L respectively, was enough to further 
improve post-ischemic functional recovery compared to groups which either received 




quinone reductase 2, a third melatonin binding site (MT3). Interestingly, a recent study has 
shown that quinone reductase 2 has a similar affinity for resveratrol and melatonin (Ferry, 
Hecht et al. 2010). We speculate that the synergy of both compounds leads to the activation 
of quinone reductase 2 as well. This could partially explain why wine-induced 
cardioprotection was not eradicated in the presence of luzindole, a non-selective inhibitor 
which binds onto MT1 and MT2, but protection was lost in melatonin-induced 
cardioprotection when luzindole was co-administered (Lamont 2009).  It would be interesting 
to investigate whether the administration of both luzindole and S29434, a novel competitive 
inhibitor of quinine reductase 2 (Reybier, Perio et al. 2011) may alter synthetic wine enriched 
with both melatonin and resveratrol induced cardioprotection. Thus, co-administration of 
melatonin and resveratrol, given at concentrations similar to those found in red wine, had an 
synergistic effect and protected the myocardium against IR injury by improving functional 
recovery to a better degree than their own individual parts. Interestingly, rats pre-treated with 
synthetic wine (12% in alcohol) enriched with either resveratrol or melatonin did not 
demonstrate improved post-ischemic functional recovery or reduced infarct size. Perhaps 
components within the synthetic wine have a quenching effect on melatonin and resveratrol 
and thus these two components are unable to fully execute their cardioprotective 
capabilities.  
 
4.4 Role of antioxidants in synthetic wine induced cardioprotection  
Reperfusion injury worsens myocardial injury and considerable evidence attributes free 
radicals either produced by the cardiomyocyte or by inflammatory cells (Bolli, Jeroudi et al. 
1989) as an early event in IR injury. Once produced, free radicals can lead to cellular 
damage through multiple pathways including direct damage to membranes (Toyokuni 1999) 
or indirect damage through activation of pro-apoptotic pathways (Bialik, Cryns et al. 1999). 
While using antioxidants to scavenge free radicals may be a potential approach to reduce 
myocardial IR injury, multiple clinical trials using antioxidant therapies have been largely 
disappointing see review (Steinhubl 2008). 
Well known components of red wine such as resveratrol and melatonin are suggested to 
protect against IR injury through their antioxidant properties. In this study, chronic 
consumption of the various treatments did not increase antioxidant enzymes catalase and 
SOD activity or reduce the amount of lipid peroxidation. In addition, most of the treatments 
did not significantly increase the total antioxidant capacity of the animals receiving the 
treatment. Surprisingly, animals pre-treated with synthetic wine or water enriched with both 




significant decrease in their total antioxidant capacity. Paradoxically, these are the two 
groups which demonstrated improved post-ishemic recovery relative to the animals which 
received water only. Our experiments were conducted in baseline conditions and it would be 
of interest to explore the antioxidant status of the rats in both plasma and heart tissue 
following an IR insult. Of note, free radicals have been implicated as mediators of diverse 
physiologic and pathophysiologic events however, there is growing evidence which suggests 
that free radicals may have a dual effect, becoming protective in some pathological 
conditions. ROS generation has been suggested to mediate in ischemic preconditioning see 
review (Yellon, Downey 2003) and the role of free radicals in TNFα induced cardioprotection 
(Lecour, Rochette et al. 2005). 
 
 
4.5 Limitations and future prospects  
 
a) It would be of interest to simulate our experiments using an in vivo model of IR injury, 
as the isolated heart does not take into consideration the confounding effects of other 
organs systemic and circulating neuro-hormonal factors. 
b)  The oxidant and antioxidant results predominantly did not show any level of 
significance. It would have been interesting if animal tissue such as the heart and 
liver were examined to see if there were any changes in the pro- and anti-oxidant 
status. In addition, if hearts subjected to IR injury were examined for changes in the 
oxidative profile, there could have been more robust differences in our measures. 
c) During the duration of this project, the building in which our animals were being 
housed was being refurbished. The noise from the on-going construction could have 
stressed the animals and thus, might have been responsible for the lack of 
differences between the groups when measuring infarct size. 
d) Most of the results demonstrated large variation within groups. If the sample size 
within each group were to be increased statistical significance could possibly be 
reached 
e) There was no way to ascertain if all the rats in one cage received the same amount 
of treatment in a day. Thus, giving the rats their treatment through oral gavage would 
be a more accurate method. 
f) In this study, we only used resveratrol and melatonin to enrich the synthetic wine. 
There are other components which could be added into the matrix such as 




g) This study demonstrated synthetic wine enriched with both resveratrol and melatonin 
improved post-ischemic functional recovery. However, we did not elucidate through 
which mechanism it achieves this effect. It would be of interest if we could use both 
melatonin inhibitors luzindole and S29434 and examine if the treatment elicits it effect 
through pro-survival SAFE and RISK pathways. 
 
4.6 Conclusion 
In conclusion, our data strongly suggest that chronic and moderate consumption of synthetic 
wine enriched with both melatonin and resveratrol protects against IR injury. Our data did not 
support a role for alcohol in red wine-induced cardioprotection. Our findings support the use 
of dietary concentrations of combined resveratrol and melatonin as a safe, inexpensive and 
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Trace elements  
Manganese(II)Chloride 
Tetrahydrate 
Zinc chloride  
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Cobalt(II) nitrate hexahydrate 






30   µg 
15   µg 
  5   µg 
30   µg 
25   µg 














100  mg 
   2   mg 
   2   mg 
   1   mg 
0.5   mg 
0.2   mg 
0.2   mg 
0.125 mg 
 0.2  mg 
Lipids/Oxygen 
Ergosterol 
Tween 80  















Folin-ciocalteau assay  
a) 20% (m/v) Gallic acid in ethanol 
               0.5 g of Gallic acid in 10mL of ethanol  
b) Gallic acid standard curve: 
100µL of Gallic acid + 9900µL distilled water=500mg/L 
400µL 0f Gallic acid + 100µL distilled water=400mg/L 
300µL of Gallic acid + 200µL distilled water=300mg/L 
200µL of Gallic acid + 300µL distilled water=200mg/L 
100µL of Gallic acid + 400µL distilled water=100mg/L 
 50µL of Gallic acid + 450µL distilled water=50mg/L 
 0µL of Gallic acid + 500µL distilled water=0mg/L 
 
c) 20% (m/v) Sodium carbonate (𝐍𝐚𝟐𝐂𝐎𝟑) 
Measure 20g anhydrous Na2CO3 in 80mL distilled water and bring to boil. 
After cooling, add few crystals of Na2CO3 and leave for 24 hours. Filter and add 























Oxygen radical absorbance capacity (ORAC) assay  
a) Phosphate buffer(0.075M pH=7.4): 
          0.75M K2HPO4 .3H2O (MW= 228.23: 85.6g →500mL Distilled water) 
          0.75M Na2H2P04. H2O     (MW= 137.99: 51.8g →500mL Distilled water) 
          90mL K2HPO4 +24mL Na2H2P04 
          Make up to 900mL then pH , make up to 1L 
b) Trolox(6-OH-2,5,7,8-tetromethylchroman-2-carboxylic acid) standard curve 
0.005g Trolox in 200μl ethanol = 100mM 
1. 100μl + 9.9 μl buffer =1000μM 
2. 1mL + 9mL buffer =100μM  
3. 300μl +300 μl buffer =50 μM  
4. 300μl +300 μl buffer =25 μM  
5. 300μl +300 μl buffer =12.5 μM  
6. 300μl +300 μl buffer =6.25 μM  
7. 300μl +300 μl buffer =3.13 μM  
8. 300μl +300 μl buffer =1.37 μM  
c) Fluorescein (3,6-dihydroxyspiro(isoberyofuran-1(3H),9(9H)-xanthen) (disodium) 
Stock 1: 0.0225g in 50mL buffer (0.0011959 mol/L) 
Stock 2: 50μl stock 1 in 10mL buffer 1 in 10m/L buffer (5.98μmol/L) 
Working solution: 320μl stock 2 in 20mL buffer (95.7nmol/L) 
d) AAPH: (2,2'-Azobis(2-amidinopropane) dihydrochloride) 
NB: Prepare immediately before use in phosphate buffer pre washed to 37°C 
           32.1 μmol per well 
 0.696 + 7840 warm buffer 
 


























































Triphenyltetrazolium chloride staining for defrosted heart sections 
 




4    
in 1000mL distilled water  
Solution 2: 100mM  Dibasic sodium phosphate 
14.2g Na2 HPO4 in 1000mL distilled water  
 
Method used for 1% Triphenyltetrazolium chloride solution 
Mix 4 parts solution 2 : 1 part solution 1 and titrate to pH 7.4 
























Solubility of compounds at 20°C 
 Resveratrol : 0.03g/L in water at 20°C 
                          50.0g/L in ethanol at 20°C 
 Melatonin: 2g/L in water at 20°C 
                      182g/L in ethanol at 20°C 
 
Preparation of Melatonin (75 ng /L) 
 Measure 15mg into 200ml of solvent (ethanol) to create stock solution (A) 
 Pipette 10µL of solution (A) into 10000µL of ethanol to create solution (B) 
 Pipette 10 µL of solution (B) into 10000µL of synthetic wine to create solution (C) 
 Dilute 1 part of solution (C) into 7 parts of distilled water 
Preparation of Resveratrol  (100µg/L) 
 Measure 10mg in 100ml of ethanol to create stock solution (A) 
 Pipette 10 µL of solution (A) into 10000µL of wine to create solution (B) 
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